Radiolabeled ether dendrimer conjugates for PET imaging and radiotherapy
Patent Information
- Application Number
- JP2023526255
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-07
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2041-10-29
AI Technical Summary
Current imaging techniques lack specificity and sensitivity for detecting activated microglia due to the challenges of the blood-brain barrier and the non-specificity of biomarkers like TSPO, necessitating the development of non-invasive, specific imaging probes for neuroinflammation and cancer detection.
Development of radionuclide-conjugated hydroxyl-terminated dendrimers that cross the blood-brain barrier and selectively target activated microglia, allowing for PET imaging and radiotherapy by conjugating radionuclides like 18F, 89Zr, or 177Lu with dendrimers via ether linkages.
The dendrimer conjugates provide stable PET imaging and targeted radiotherapy for neuroinflammation and cancer, enhancing specificity and sensitivity by selectively accumulating in reactive microglia and tumors, while maintaining stability in vivo.
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63 / 253,308, filed October 7, 2021, U.S. Provisional Patent Application No. 63 / 187,851, filed May 12, 2021, and U.S. Provisional Patent Application No. 63 / 108,230, filed October 30, 2020, each of which is hereby incorporated by reference in its entirety. [Background technology]
[0002] background Microglia are key resident immune cells in the brain, maintaining brain homeostasis by preventing pathogen invasion, constantly clearing cellular debris from the brain parenchyma, and repairing neuronal injury. Microglia / macrophages play a crucial role after central nervous system (CNS) injury and can have both protective and detrimental effects depending on the timing and type of injury. Microglial activation is a key pathological event in early brain injury, leading to neuronal injury and further disease progression (Li, et al., Nature Reviews Immunology, 2017, 18, 225; Hernadez-Ontiveros, et al., Frontiers in Neurology 2013, 4 (30); Ramlackhansingh, et al., Annals of Neurology 2011, 70 (3), 374-383).
[0003] The development of smart, specific, and non-invasive preclinical and clinical imaging probes for tracking activated microglia is necessary. In particular, tools and systems are needed to evaluate the in vivo efficacy of novel neuroinflammatory treatments. However, the development of nanoprobes for imaging neuroinflammation must overcome challenges related to the blood-brain barrier (BBB), brain tissue penetration, and the specificity of targeting reactive microglia.
[0004] Positron emission tomography (PET) has been widely applied in clinical oncology for cancer diagnosis, neurology for brain function evaluation, cardiology for cardiac function evaluation, and infectious diseases. Translocator protein 18 kDa (TSPO) is the most well-studied biomarker for PET imaging of the brain, and several TSPO ligand-based PET tracers are currently in use. However, the lack of cell specificity of TSPO poses a problem for quantification, which necessitates the need for highly sensitive PET probes specific for activated microglia (Vaquero, et al, Annu Rev Biomed Eng 2015, 17, 385-414; Narayanaswami, et al., Mol Imaging 2018, 17, 1536012118792317-1536012118792317; Janssen, et al., Academic Press: 2019; Vol. 165, pp 371-399; Werry, et al., Int J Mol Sci 2019, 20 (13), 3161; Papadopoulos, Experimental Neurology 2009, 219 (1), 53-57).
[0005] Other imaging techniques include computed tomography (CT) and magnetic resonance imaging (MRI). Magnetic resonance imaging (MRI) uses radio waves in the presence of a strong magnetic field surrounding the opening of the MRI machine while the patient lies down, causing tissues to emit their own radio waves. Different tissues (including tumors) emit stronger or weaker signals based on their chemical makeup, and a picture of the body organ can be displayed on a computer screen. Like a CT scan, an MRI can create three-dimensional images of body parts, but MRI is sometimes more sensitive than a CT scan at identifying soft tissue. Thus, in some aspects, the present disclosure provides compositions and methods for non-invasive detection of inflammation or neuroinflammation sites in a subject, as well as methods for making and using the same. In some aspects, the present disclosure provides compositions for in vivo molecular imaging of cancer cells, such as metastatic cancer cells, as well as methods for making and using the same. In some aspects, the present disclosure provides compositions and methods for selectively targeting radiation therapy to cancer cells. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Vaquero et al., Annu Rev Biomed Eng (2015) 17, 385–414 [Non-patent document 2] Narayanaswami et al., Mol Imaging (2018) 17, 1536012118792317~1536012118792317 [Non-patent document 3] Janssen et al., Academic Press (2019) Vol.165, pp371~399 [Non-patent document 4] Werry et al., Int J Mol Sci(2019)20(13)3161 [Non-patent document 5] Papadopoulos, Experimental Neurology (2009) 219(1) 53~57 Summary of the Invention [Means for solving the problem]
[0007] overview Aspects of the present disclosure include radionuclides, e.g. 18 F (fluorine-18), 89 Zr (zirconium-89), 90 Y (yttrium-90), and 177The present disclosure relates to the discovery that dendrimers (e.g., hydroxyl PAMAM dendrimers) conjugated or complexed with Lu (ruthenium-177) can cross the BBB in the presence of reactive microglia and selectively target these microglia after systemic administration. In some embodiments, these conjugates are stable positron emission tomography (PET) imaging probes for noninvasive and specific imaging of reactive microglia in vivo and stable radiotherapeutic agents for the treatment of tumors. In some aspects, the present disclosure provides compositions and methods for detecting one or more sites of inflammation in a subject in need thereof. In some aspects, the present disclosure provides compositions and methods for treating cancer in a subject in need thereof.
[0008] In some aspects, the present disclosure provides compositions of hydroxyl-terminated dendrimers conjugated to one or more imaging agents via ether linkages. In some embodiments, the hydroxyl-terminated dendrimers are conjugated to imaging agents, which may include radionuclides or MRI contrast agents. In some embodiments, the dendrimer conjugates selectively accumulate in reactive microglia at sites of inflammation and in reactive immune cells in tumors as stable imaging probes or radiotherapeutic agents in vivo. In some embodiments, the dendrimer conjugates also treat sites of inflammation or cancer, for example, by selectively delivering radiotherapeutic agents to the site of inflammation or cancer. In other embodiments, the dendrimer conjugates comprise one or more additional active agents. Thus, in some embodiments, the dendrimer conjugates deliver one or more additional active agents to sites of inflammation, neuroinflammation, or tumors with increased stability in vivo. In some embodiments, the radionuclides and / or MRI contrast agents are attached to the dendrimer via ether linkages.
[0009] In some aspects, the present disclosure provides a composition comprising a compound comprising a dendrimer conjugated to a radionuclide or MRI contrast agent through an ester, ether, or amide linkage. In some embodiments, the dendrimer comprises a high density of surface hydroxyl groups. In some embodiments, the dendrimer is conjugated to a radionuclide or MRI contrast agent through an ether or amide linkage. In some embodiments, the dendrimer is conjugated to a radionuclide or MRI contrast agent through an ether linkage.
[0010] In some embodiments, the radionuclide or MRI contrast agent is conjugated to an ester, ether, or amide linkage through a spacer. In some embodiments, the spacer comprises an alkyl group, a heteroalkyl group, and / or an alkylaryl group. In some embodiments, the spacer comprises a peptide. In some embodiments, the spacer comprises polyethylene glycol.
[0011] In some embodiments, conjugation of the radionuclide or MRI contrast agent occurs to less than 50% of the total surface functional groups of the dendrimer available prior to conjugation, hi some embodiments, conjugation of the radionuclide or MRI contrast agent occurs to less than 5%, less than 10%, less than 20%, less than 30%, or less than 40% of the total surface functional groups of the dendrimer available prior to conjugation.
[0012] In some embodiments, the radionuclide is 18 F, 51 Mn, 52 Fe, 60 Cu, 68 Ga, 72 As, 94m Tc, 110 In, 18 F, 124 I, 125 I, 131 I, 123 I, 77 Br, 76 Br, 99m Tc, 51 Cr, 67Ga, 68 Ga, 47 Sc, 51 Cr, 167 Tm, 141 Ce, 111 In, 168 Yb, 175 Yb, 140 La, 90 Y, 88 Y, 153 Sm, 166 Ho, 165 Dy, 166 Dy, 62 Cu, 64 Cu, 67 Cu, 97 Ru, 103 Ru, 186 Re, 188 Re, 203 Pb, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 149 Pm, 161 Tb, 177 Lu, 225 Ac, 198 Au, 199 Au, and 89 In some embodiments, the radionuclide is selected from the group consisting of: 18 F, 89 Zr, 90 Y, or 177 In some embodiments, the MRI contrast agent is selected from the group consisting of Gd, Mn, BaSO4, iron oxide, and iron platinum. In some embodiments, the MRI contrast agent is Gd.
[0013] In some embodiments, the dendrimer is selected from the group consisting of polyamidoamine (PAMAM) dendrimers, polypropylamine (POPAM) dendrimers, polyethyleneimine dendrimers, polylysine dendrimers, polyester dendrimers, iptycene dendrimers, aliphatic poly(ether) dendrimers, and aromatic polyether dendrimers.
[0014] In some embodiments, the zeta potential of the compound is between -25 mV and 25 mV. In some embodiments, the zeta potential of the compound is between -20 mV and 20 mV, between -10 mV and 10 mV, between -10 mV and 5 mV, between -5 mV and 5 mV, or between -2 mV and 2 mV. In some embodiments, the surface charge of the compound is neutral or near-neutral.
[0015] In some aspects, the present disclosure provides a method for detecting one or more inflammatory sites in a subject in need thereof.In some aspects, the present disclosure provides a method for imaging one or more inflammatory sites in a subject in need thereof.In some embodiments, the method comprises administering to a subject an effective amount of the composition described herein.For example, in some embodiments, the composition comprises a compound comprising a dendrimer conjugated to a radionuclide or MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.
[0016] In some embodiments, the method selectively delivers one or more radionuclides or magnetic resonance imaging (MRI) contrast agents to a target site in a recipient. In some embodiments, the method comprises administering to a subject a formulation comprising a hydroxyl-terminated dendrimer conjugated to one or more radionuclides or MRI contrast agents via an ether linkage. Exemplary radionuclides that can be delivered include: 18 F, 51 Mn, 52 Fe, 60 Cu, 68 Ga, 72 As, 94 mTc, or 110 In, 18 F, 124 I, 125 I, 131 I, 123 I, 77 Br, 76 Br, 99m Tc, 51 Cr, 67 Ga, 68 Ga,47 Sc, 51 Cr, 167 Tm, 141 Ce, 111 In, 168 Yb, 175 Yb, 140 La, 90 Y, 88 Y, 153 Sm, 166 Ho, 165 Dy, 166 Dy, 62 Cu, 64 Cu, 67 Cu, 97 Ru, 103 Ru, 186 Re, 188 Re, 203 Pb, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117 mSn, 149 Pm, 161 Tb, 177 Lu, 225 Ac, 198 Au and 199 Au, or 89 Exemplary MRI contrast agents that can be delivered include Gd, Mn, BaSO4, iron oxide, and iron platinum.
[0017] In some embodiments, the method delivers one or more radionuclides or MRI contrast agents to a subject in an amount effective to achieve a physiological response in the subject. The dendrimer optionally complexes, covalently conjugates, or intramolecularly disperses or encapsulates one or more additional active agents, such as therapeutic or prophylactic agents. In some embodiments, the formulation is systemically administered to a subject in an amount effective to detect, diagnose, or monitor one or more inflammatory sites or cancer in the recipient, and / or treat, alleviate, or prevent one or more symptoms of inflammation or cancer in the subject. Exemplary inflammatory sites or cancers that can be detected, diagnosed, monitored, and / or treated include sites of autoimmune disease or disorder, sites of neuroinflammation in the brain, and solid tumors, including brain tumors. Additional exemplary inflammatory sites include sites of inflammation associated with one or more inflammatory diseases, or associated with sepsis or septic shock, or caused by any mechanism of macrophage activation, including macrophage activation syndrome. In some embodiments, the one or more inflammatory sites in the subject include one or more neuroinflammatory sites in the central nervous system. In some embodiments, the one or more neuroinflammatory sites in the central nervous system in the subject are associated with Alzheimer's disease. In some embodiments, the one or more inflammatory sites in the subject are associated with amyotrophic lateral sclerosis (ALS). In some embodiments, the dendrimer is a fourth-generation, fifth-generation, or sixth-generation poly(amidoamine) (PAMAM) hydroxyl-terminated dendrimer.
[0018] In some aspects, the present disclosure provides compositions and methods for detecting cancer cells in a subject in vivo. In some embodiments, the method involves administering to the subject one or more hydroxyl-terminated dendrimers conjugated or complexed with one or more radionuclides and / or one or more MRI contrast agents that selectively target tumor regions. In some embodiments, the subject can then be imaged using a molecular imaging device to detect the hydroxyl-terminated dendrimers conjugated or complexed with one or more radionuclides in the subject. In some embodiments, the subject can also be imaged using an MRI scanner to detect the hydroxyl-terminated dendrimers conjugated or complexed with one or more MRI contrast agents in the subject. Thus, in some embodiments, detection of labeled hydroxyl-terminated dendrimers in the subject's organs or tissues can be an indicator of cancer cells in the organ.
[0019] In some embodiments, the cancer cells may be primary tumor or metastatic cancer cells. Thus, in some embodiments, the method involves administering a dendrimer conjugated or complexed with one or more radionuclides to a subject diagnosed with a primary tumor to identify metastatic cancer cells. In other embodiments, the method involves administering a dendrimer conjugated or complexed with one or more radionuclides to a subject at risk of cancer to detect primary tumors or occult tumors. Non-limiting examples of cancer cells that can be detected by the methods of the present disclosure include renal cell carcinoma.
[0020] In some aspects, the present disclosure provides a method for treating neurodegenerative disorders.In some embodiments, the method comprises administering an effective amount of the composition described herein to a subject in need thereof.In some embodiments, the composition comprises a compound comprising a dendrimer conjugated to a radionuclide or MRI contrast agent through ester, ether or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.In some embodiments, the neurodegenerative disorder is Alzheimer's disease.In some embodiments, the neurodegenerative disorder is ALS.
[0021] The exemplary device for use in molecular imaging includes, for example, the device for positron emission tomography (PET) scanning; the device for computer tomography (CT) and nuclear medicine imaging; the device for magnetic resonance imaging (MRI).In some embodiments, the molecular imaging device is the gamma camera suitable for positron emission tomography (PET) scanning and MRI scanner.
[0022] In some embodiments, the preparation can be formulated for intravenous administration or enteral administration to subject.In some embodiments, the preparation is administered before, together with, after, or alternately with one or more additional procedures for treatment or therapy.Exemplary additional procedures include administering one or more therapeutic, prophylactic, and / or diagnostic agents to prevent or treat one or more symptoms of inflammation, neuroinflammation, and cancer-related diseases or conditions.
[0023] In some embodiments, the present disclosure provides pharmaceutical formulations of hydroxyl dendrimers complexed with, covalently conjugated to, or encapsulated within one or more radionuclides. In some embodiments, the present disclosure provides kits comprising hydroxyl dendrimers complexed with, covalently conjugated to, or encapsulated within one or more radionuclides or one or more MRI contrast agents.
[0024] In some embodiments, the present disclosure provides methods of making hydroxyl dendrimers complexed with, covalently conjugated to, or encapsulated within, one or more radionuclides. [Brief explanation of the drawings]
[0025] [Figure 1] Figure 1 is a schematic showing the synthetic route to 18F-labeled hydroxyl dendrimers. Reagents and conditions: (i) DMSO, 2% NaOH solution, room temperature, ON; (ii) CuBr(I), N,N,N',N'',N''-pentamethyldiethylenetriamine, 2 hours, 60 °C; (iii) KF, K2CO3, cryptand 222, 105 °C, 20 minutes, DMSO.
[0026] [Figure 2] FIG. 2 is a bar graph showing the in vitro plasma stability of fluorinated dendrimers, showing highly stable conjugates with negligible defluorination.
[0027] [Figure 3] Figure 3 shows a schematic diagram of the synthetic route to 89Zr-labeled hydroxyl dendrimers. Reagents and conditions: (i) allyl bromide, CS2CO3, TBAI, DMF, room temperature, ON; (ii) cysteamine, 2,2-dimethoxy-2-phenylacetophenone, DMF, 365 nm, 8 hours, room temperature; (iii) SCN-Bn-deferoxamine, DIPEA, DMSO, room temperature, ON; (iv) 89Zr4+, HEPES buffer, pH 7.5, room temperature, 60 minutes.
[0028] [Figure 4] FIG. 4 is a bar graph showing the in vitro plasma stability of Zr-labeled dendrimers, showing highly stable conjugates with negligible release.
[0029] [Figure 5]Figure 5 shows a schematic diagram of the synthetic route to Y-labeled hydroxyl dendrimers. Reagents and conditions: (i) DMF, CuSO4.5HO, sodium ascorbate, room temperature, ON; (ii) DMSO, DIPEA, room temperature, pH 7.5, ON; (iii) yttrium chloride, ammonium acetate buffer (0.5 M, pH approximately 6.5-7.5), 100 °C, 30-60 min.
[0030] [Figure 6] Figure 6 is a schematic showing the synthetic route to the Y-labeled hydroxyl dendrimer-antitumor drug combination. Reagents and conditions: (i) DMF, CuSO4.5HO, sodium ascorbate, room temperature, ON; (ii) DMSO, DIPEA, room temperature, pH 7.5, ON; (iii) yttrium chloride, ammonium acetate buffer (0.5 M, pH approximately 6.5-7.5), 100°C, 30-60 min.
[0031] [Figure 7-1]Figures 7A-7E show the results of imaging neuroinflammation and neurodegenerative diseases using 18F-labeled dendrimers. Figure 7A shows a summary of the extent of hydroxyl dendrimer localization in reactive microglia as a function of blood-brain barrier (BBB) disruption in multiple CNS injury models. Figure 7B shows images depicting the histology of brain sections containing beta-amyloid plaques measured by confocal fluorescence microscopy from animals sacrificed 48 hours post-dosing, demonstrating selective uptake of Cy5-labeled hydroxyl dendrimer after a single IV administration (55 mg / kg) to 7-month-old 5xFAD mice. Figure 7C shows images representing total brain PET / CT images at 50–60 min after tracer administration and 24 h after injection of saline or LPS (10 mg / kg); LPS-injected mice exhibited variable mouse sepsis scores indicative of the severity of their symptoms. PET imaging revealed mice with low and high sepsis scores, demonstrating the ability of 18F-OP-801 to detect increasing levels of inflammation that correlate with symptom severity. Figure 7D shows images demonstrating whole-body PET / CT images, which revealed significantly higher uptake of 18F-OP-801 in LPS-injected mice compared to mice given saline only. Figure 7E is a line graph showing group-averaged time-activity curves (TCA) on a whole-brain scale as %ID / g over a 60-min period in saline- or LPS-injected mice. Figure 7F is a bar graph showing quantification of total brain PET images from 50 to 60 min, demonstrating significantly elevated 18F-OP-801 uptake in the cortex, medulla, olfactory bulb, and pons in LPS-injected (n = 10) and saline-injected (n = 6) female mice. *: p < 0.05, **: p < 0.01. Figures 7G and 7H are bar graphs showing total 18F-OP-801 PET quantification from 25 to 35 min in organs including the liver and lungs (Figure 7G) and the whole brain and hippocampus (Figure 7H) in LPS-injected (n = 6) and saline-injected (n = 5) mice. *: p = 0.045. Figure 7I is a bar graph showing ex vivo 18F-OP-801 biodistribution at 70 min post-injection in LPS-injected (n = 4, excluding two low-MSS-score mice) and saline-injected (n = 5) mice.Figure 7J shows imaging from autoradiography of a 40-µm-thick sagittal brain section overlaid with Nissl staining of the same section at 70 min post-injection from a representative saline vs. high-MSS LPS mouse. Figure 7K is a plot of LPS MSS score in the whole brain from 50-60 min PET versus %ID / g, showing linear regression and 95% confidence intervals. Figure 7L is a bar graph showing the plasma stability of 18F-labeled hydroxyl dendrimer (18F-OP-801) (n = 4 female mice per time point). Figures 7M and 7N show a comparison of PET imaging with 18F-GE180 (Figure 7M) and 18F-OP-801 (Figure 7N) in 3.75-month-old 5xFAD mice and age-matched wild-type controls. Figure 7O shows a comparison of PET imaging with 18F-OP-801 in 5-month-old 5xFAD mice and age-matched wild-type controls. [Figure 7-2] Same as above. [Figure 7-3] Same as above. [Figure 7-4] Same as above. [Figure 7-5] Same as above. [Figure 7-6] Same as above. [Figure 7-7] Same as above.
[0032] [Figure 8] FIG. 8 shows the synthesis of D6-B483.
[0033] [Figure 9] 9A-9B show the selective uptake of 111In-D6-B483 in the brain and solid tumors.
[0034] [Figure 10] FIG. 10 shows the localization of 111In-D6-B483 in large tumors.
[0035] [Figure 11] FIG. 11 shows the localization of 111In-D6-B483 in small tumors. DETAILED DESCRIPTION OF THE INVENTION
[0036] Detailed Description of the Invention Among other aspects, the present disclosure provides methods for treating radionuclides, e.g. 18 F (fluorine-18) and / or 89 The present invention relates to the discovery that hydroxylated dendrimers, e.g., hydroxyl PAMAM dendrimers, complexed or conjugated with Zr (zirconium-89) can cross the damaged BBB and selectively target activated microglia in the absence of any targeting ligand upon systemic administration as stable positron emission tomography (PET) imaging probes for non-invasive and specific imaging of activated microglia. 18 F or 89 Hydroxylated dendrimers (e.g., hydroxyl PAMAM dendrimers) complexed or conjugated with Zr are not observed in brain cells of healthy brains. Without wishing to be bound by theory, the mechanism of selective uptake may be due to uptake by glia with increased phagocytic activation, resulting in the selective uptake of radionuclides, e.g., 18 F or 89 This is thought to be related to the ability of hydroxyl dendrimers complexed or conjugated with Zr to diffuse well in the brain. 18 F or 89 Hydroxyl dendrimers complexed or conjugated with Zr are non-toxic even at intravenous doses >500 mg / kg and are excreted intact through the kidney.
[0037] Thus, in some aspects, the present disclosure provides a method for using a radionuclide, e.g., a PET-based PET probe, to diagnose, detect, and / or image sites of inflammation, e.g., neuroinflammation, in a subject in need thereof via PET imaging. 18 F (fluorine-18) or 89 In some embodiments, compositions of dendrimer complexes are provided, comprising dendrimers complexed or conjugated with Zr. 18 F or 89The Zr-complexed dendrimer compositions are suitable for delivering one or more active agents, particularly one or more active agents for diagnosing, detecting, and / or imaging sites of inflammation, e.g., neuroinflammation, in a subject in need thereof. In some embodiments, the compositions are also suitable for diagnosing, detecting, and / or imaging cancer cells in vivo and / or for treating or ameliorating one or more symptoms associated with cancer.
[0038] In some aspects, the present disclosure provides a method for the preparation of radionuclides, e.g. 18 F or 89 The present inventors have discovered that hydroxyl-terminated dendrimers complexed or conjugated with Zr and further conjugated to one or more active agents via ether linkages have enhanced stability in vivo. 18 F or 89 It is recognized and understood that hydroxyl-terminated dendrimers labeled with Zr and further conjugated to one or more active agents via ether linkages selectively deliver the active agents to sites of inflammation, neuroinflammation, and / or tumors in vivo.
[0039] Thus, in some aspects, the present disclosure provides a dendrimer-based radionuclide-based compound comprising one or more prophylactic, therapeutic, and / or diagnostic agents complexed and / or conjugated in a dendrimer, e.g., 18 F or 89Compositions are provided of hydroxyl-terminated dendrimers complexed or conjugated with Zr. In some embodiments, one or more active agents are complexed and / or conjugated in the dendrimer complex at a concentration of about 0.01% to about 30% by weight, e.g., about 1% to about 20% by weight, or about 5% to about 20% by weight. In some embodiments, the hydroxyl groups of the hydroxyl-terminated dendrimer are covalently conjugated to one or more active agents via at least one ether linkage, optionally via one or more linkers / spacers. In some embodiments, the surface groups of the hydroxyl-terminated dendrimer are modified via an etherification reaction prior to conjugation to one or more linkers and active agents. In some embodiments, when one or more linkers are present between the dendrimer and the active agent, the covalent bond between the surface group of the dendrimer and the linker is an ether bond, as shown, for example, in Figures 1 and 3.
[0040] The presence of additional agents can affect the zeta potential or surface charge of the particles. In some embodiments, the zeta potential of the dendrimer is between -100 mV and 100 mV, between -50 mV and 50 mV, between -25 mV and 25 mV, between -20 mV and 20 mV, between -10 mV and 10 mV, between -10 mV and 5 mV, between -5 mV and 5 mV, or between -2 mV and 2 mV. In some embodiments, the surface charge is neutral or near-neutral. The above ranges encompass all values between -100 mV and 100 mV.
[0041] dendrimer Dendrimers are three-dimensional, highly branched, monodisperse, spherical, and multivalent macromolecules containing a high density of surface end groups (Tomalia, D.A., et al., Biochemical Society Transactions, 35, 61 (2007); and Sharma, A., et al., ACS Macro Letters, 3, 1079 (2014)).
[0042] In the past few decades, dendrimers have attracted much attention from the scientific community, especially in the field of targeted molecular delivery, due to their precisely defined, highly branched, and multivalent architecture. These dendritic, spherical macromolecules can be efficiently developed in a highly controlled synthetic manner, allowing for easy manipulation of surface groups to introduce diverse ligands and other therapeutically relevant bioactive molecules. Their unique structural and physical features make dendrimers useful as nanocarriers for various biomedical applications, including targeted drug / gene delivery, imaging, and diagnostics (Sharma, A., et al., RSC Advances, 4, 19242 (2014); Caminade, A.-M., et al., Journal of Materials Chemistry B, 2, 4055 (2014); Esfand, R., et al., Drug Discovery Today, 6, 427 (2001); and Kannan, RM, et al., Journal of Internal Medicine, 276, 579 (2014)).
[0043] Dendrimer surface groups have a significant impact on their biodistribution (Nance, E., et al., Biomaterials, 101, 96 (2016)). Hydroxyl-terminated fourth-generation PAMAM dendrimers (approximately 4 nm in size) cross the impaired BBB significantly more frequently (>20-fold) in rabbit models of cerebral palsy (CP) when administered systemically without any targeting ligand compared to healthy controls, selectively targeting activated microglia and astrocytes (Lesniak, W.G., et al., Mol Pharm, 10 (2013)).
[0044] In some embodiments, the term "dendrimer" includes, but is not limited to, a molecular architecture having an inner core and layers (or "generations") of repeating units attached to and extending from the inner core, each layer having one or more branch points, with the outer surface of terminal groups attached to the outermost generation. In some embodiments, dendrimers have a regular dendrimer structure or a "starburst" molecular structure.
[0045] In some embodiments, the dendrimer has a diameter of between about 1 nm and about 50 nm, between about 1 nm and about 20 nm, between about 1 nm and about 10 nm, or between about 1 nm and about 5 nm. In some embodiments, the diameter is between about 1 nm and about 2 nm. Conjugates, in some embodiments, are generally within the same size range, although larger proteins such as antibodies may increase the size by 5-15 nm. In some embodiments, the agent is encapsulated or conjugated to the dendrimer at an agent to dendrimer ratio of between 1:1 and 4:1 for larger generation dendrimers. In some embodiments, the dendrimer has a diameter effective for targeting and long-term retention in hepatocytes.
[0046] In some embodiments, the dendrimer has a molecular weight between about 500 daltons and about 100,000 daltons, between about 500 daltons and about 50,000 daltons, or between about 1,000 daltons and about 20,000 daltons. The molecular weight is a function of the monomer molecular weight.
[0047] Suitable dendrimer scaffolds that can be used include poly(amidoamine) or STARBURST™ dendrimers, also known as PAMAM, polypropylamine (POPAM), polyethyleneimine, polylysine, polyesters, iptycene, aliphatic poly(ether), and / or aromatic polyether dendrimers. The dendrimers can be carboxy-, amine-, and / or hydroxyl-terminated. In some embodiments, the dendrimers are hydroxyl-terminated. Each dendrimer in a dendrimer complex can be of the same, similar, or different chemical nature as the other dendrimers (e.g., a first dendrimer can comprise a PAMAM dendrimer, while a second dendrimer can be a POPAM dendrimer).
[0048] The term "PAMAM dendrimer" refers to a poly(amidoamine) dendrimer, which may contain different cores comprising amidoamine components and may have carboxy, amine, and hydroxyl termini of any generation, including, but not limited to, a first-generation PAMAM dendrimer, a second-generation PAMAM dendrimer, a third-generation PAMAM dendrimer, a fourth-generation PAMAM dendrimer, a fifth-generation PAMAM dendrimer, a sixth-generation PAMAM dendrimer, a seventh-generation PAMAM dendrimer, an eighth-generation PAMAM dendrimer, a ninth-generation PAMAM dendrimer, or a tenth-generation PAMAM dendrimer. In some embodiments, the dendrimer is soluble in the formulation and is a generation ("G") 4, 5, or 6 dendrimer (i.e., a G4-G6 dendrimer), and / or a G4-G10 dendrimer, a G6-G10 dendrimer, or a G2-G10 dendrimer. The dendrimer may have hydroxyl groups attached to its functional surface groups, hi some embodiments, the dendrimer is a fourth, fifth, sixth, seventh, or eighth generation hydroxyl-terminated dendrimer (e.g., a poly(amidoamine) dendrimer).
[0049] In some embodiments, the dendrimer comprises multiple hydroxyl groups. Some exemplary high-density hydroxyl-group-containing dendrimers include commercially available polyester dendritic polymers, such as hyperbranched 2,2-bis(hydroxyl-methyl)propionic acid polyester polymers (e.g., hyperbranched bis-MPA polyester-64-hydroxyl, 4th generation), and dendritic polyglycerols.
[0050] In some embodiments, the high-density hydroxyl-containing dendrimer is an oligoethylene glycol (OEG)-like dendrimer. For example, second-generation OEG dendrimers (D2-OH-60) can be synthesized using highly efficient, robust, and atom-economical chemical reactions, such as Cu(I)-catalyzed alkyne-azide click chemistry and photocatalytic thiol-ene click chemistry. Very low-generation, high-density polyol dendrimers with minimal reaction steps can be achieved by using an orthogonal hypermonomer and hypercore strategy, as described, for example, in WO2019094952. In some embodiments, the dendrimer backbone has non-cleavable polyether bonds throughout the structure to avoid dendrimer collapse in vivo and enable elimination of such dendrimers as a single entity from the body (non-biodegradable).
[0051] In some embodiments, the dendrimer specifically targets a particular tissue region and / or cell type, e.g., liver cells. In some embodiments, the dendrimer specifically targets a particular tissue region and / or cell type without a targeting moiety.
[0052] In some embodiments, the dendrimer has multiple hydroxyl (-OH) groups at the periphery of the dendrimer. The surface density of the hydroxyl (-OH) groups is, in some embodiments, at least 1 OH group / nm 2 (number of hydroxyl surface groups / nm 2For example, in some embodiments, the surface density of hydroxyl groups is greater than 2, greater than 3, greater than 4, greater than 5, greater than 6, greater than 7, greater than 8, greater than 9, or greater than 10 OH groups / nm 2 at least 10, 15, 20, 25, 30, 35, 40, 45, 50, or more than 50 OH groups / nm 2 In a further embodiment, the surface density of hydroxyl (—OH) groups is from about 1 to about 50 OH groups / nm 2 Between 5 and 20 OH groups / nm 2 (number of hydroxyl surface groups / nm 2 surface area at 1000 kDa), but has a molecular weight between about 500 Da and about 10 kDa.
[0053] In some embodiments, dendrimers may have some of their hydroxyl groups exposed on the exterior surface and others in the interior core of the dendrimer. In some embodiments, dendrimers may have at least one OH group / nm 3 (Number of hydroxyl groups / nm 3 For example, in some embodiments, the volume density of hydroxyl groups is 2, 3, 4, 5, 6, 7, 8, 9, 10, or 10 OH groups / nm 3 , or more than 10, more than 15, more than 20, more than 25, more than 30, more than 35, more than 40, more than 45, and more than 50 OH groups / nm 3 In some embodiments, the volume density of hydroxyl groups is from about 4 to about 50 OH groups / nm 3 Between about 5 and about 30 OH groups / nm 3 Between about 10 and about 20 OH groups / nm 3 The diameter of a dendrimer can generally be determined by transmission electron microscopy and atomic force microscopy, dynamic light scattering, computational calculations, or a combination thereof, to determine surface area and volume.
[0054] In some embodiments, the dendrimer comprises a number of hydroxyl groups effective to target activated microglia at sites of disease, disorder, or injury in the CNS, inflammation, or tumor areas.
[0055] Dendrimer complexes containing imaging agents Conjugates of dendrimers conjugated with one or more diagnostic or imaging agents are described. The dendrimers can be conjugated to a radionuclide reporter suitable for scintigraphy, SPECT, or PET imaging, and / or a radionuclide suitable for radiotherapy; or to an MRI contrast agent for MRI imaging. Dendrimer conjugates are specifically contemplated in which the dendrimer is conjugated to both a chelator of a radionuclide or MRI contrast agent useful for diagnostic imaging and a chelator useful for radiotherapy; in some embodiments, the conjugation is via an ether linkage. Thus, in some embodiments, a single dendrimer / imaging agent composition can simultaneously treat and / or diagnose a disease or condition at one or more locations in the body. Similarly, radiolabeled SPECT or scintigraphy imaging agents with suitable amounts of radioactivity are also disclosed.
[0056] Suitable imaging agents can be selected based on the selection of imaging methods. For example, in some embodiments, the imaging agent is a near-infrared fluorescent dye for optical imaging, a gadolinium chelate for MRI imaging, a radionuclide for PET or SPECT imaging, or a gold nanoparticle for CT imaging.
[0057] Kind Code: A1 Compositions of dendrimers conjugated or complexed with one or more imaging probes for positron emission tomography (PET) that contain one or more radionuclides are provided.
[0058] PET is a technology that uses specialized cameras and computers to detect small amounts of radioactive tracers or radiopharmaceuticals in vivo to assess organ and tissue function. PET can detect the early onset of disease before other tests can.
[0059] PET has a half-life of approximately 110 minutes, including but not limited to, using the coincidence method. 18 F, which has a half-life of approximately 20 minutes 11 C, with a half-life of approximately 10 minutes 13 N, and has a half-life of approximately 2 minutes 15 It involves the detection of gamma rays in the form of annihilation photons from short-lived positron-emitting radioisotopes, including O. Thus, for use as PET agents, dendrimers can be coupled to various positron-emitting metal ions, e.g. 51 Mn, 52 Fe, 60 Cu, 68 Ga, 72 As, 94 mTc, or 110 The dendrimers of the present disclosure can also be conjugated or complexed with one or more radionuclides, e.g. 18 F, 124 I, 125 I, 131 I, 123 I, 77 Br, and 76 Examples of metal radionuclides for scintigraphy or radiotherapy include: 99m Tc, 51 Cr, 67 Ga, 68 Ga, 47 Sc, 51 Cr, 167 Tm, 141 Ce, 111 In, 168 Yb, 175 Yb, 140 La, 90 Y, 88 Y,153 Sm, 166 Ho, 165 Dy, 166 Dy, 62 Cu, 64 Cu, 67 Cu, 97 Ru, 103 Ru, 186 Re, 188 Re, 203 Pb, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117 mSn, 149 Pm, 161 Tb, 177 Lu, 225 Ac, 198 Au, and 199 The choice of metal is determined based on the desired therapeutic or diagnostic application. For example, for diagnostic purposes, examples of radionuclides include: 64 Cu, 67 Ga, 68 Ga, 99m Tc, and 111 For therapeutic purposes, examples of radionuclides include: 64 Cu, 90 Y, 105 Rh, 111 In, 117 mSn, 149 Pm, 153 Sm, 161 Tb, 166 Tb, 166 Dy, 166 Ho, 175 Yb, 177 Lu, 225 Ac, 186 / 188 Re, and 199 Au is an example. 99m Tc is useful for diagnostic applications due to its low cost, availability, imaging properties, and high specific activity. 99mThe nuclear and radioactive properties of Tc make this isotope an ideal scintigraphic imaging agent. This isotope has a single photon energy of 140 keV and a radioactive half-life of approximately 6 hours. 99 Mo- 99m It is readily available from Tc generators. 18 F, 4-[ 18 F] Fluorobenzaldehyde ( 18 FB), Al[ 18 F]-NOTA, 68 Ga-DOTA, and 68 Ga-NOTA is a typical radionuclide for conjugation to dendrimers for PET imaging. 153 Sm can be used with a chelator such as ethylenediaminetetramethylenephosphonic acid (EDTMP) or 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid (DOTMP).
[0060] Magnetic resonance imaging (MRI) is widely used today to evaluate brain diseases, spinal cord disorders, angiography, cardiac function, and musculoskeletal injuries. While MRI requires longer acquisition times than computed tomography (CT), it does not require the use of ionizing radiation and can be performed in any selected orientation. It features full three-dimensional (3-D) performance, excellent soft-tissue contrast, and high spatial resolution. Furthermore, MRI is well suited for morphological and functional imaging. Thus, we provide compositions of dendrimers conjugated or complexed with one or more imaging probes for magnetic resonance imaging, including one or more MRI contrast agents. Exemplary MRI contrast agents that can be delivered include Gd, Mn, BaSO4, iron oxide, and iron platinum.
[0061] Conjugation of dendrimers to imaging agents via ether linkages Described are compositions comprising hydroxyl-terminated dendrimers conjugated via ether linkages, optionally with one or more linkers / spacers, to radionuclides or MRI contrast agents. In one embodiment, 18 F is conjugated to a hydroxyl-terminated fourth generation PAMAM dendrimer, shown as compound 5 in Figure 1. In another embodiment, 89 Zr forms a complex with the hydroxyl-terminated fourth generation PAMAM dendrimer via chelation through p-SCN-Bn-deferoxamine (DFO) conjugated to the dendrimer, shown as compound 5 in Figure 3 .
[0062] In some embodiments, the covalent bond between the surface group of the dendrimer and the linker, or between the dendrimer and the radionuclide (when conjugated without any linking moiety), is stable under in vivo conditions, i.e., it is hardly cleaved when administered to a subject and / or is excreted intact from the body. For example, less than 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, or less than 0.1% of the total dendrimer conjugates cleave the active agent, such as a radionuclide, within 24 hours, 48 hours, or 72 hours after in vivo administration. In some embodiments, these covalent bonds are ether bonds. In some embodiments, the covalent bond between the surface group of the dendrimer and the linker, or between the dendrimer and the radionuclide (when conjugated without any linking moiety), is not a hydrolytically or enzymatically cleavable bond, such as an ester bond.
[0063] In some embodiments, one or more hydroxyl groups of the hydroxyl-terminated dendrimer are conjugated to one or more linking moieties and one or more radionuclides via one or more ether linkages as shown in formula (I) below: [ka] wherein D is a dendrimer (e.g., a G2-G10 dendrimer, such as a G2-G10 poly(amidoamine) (PAMAM) dendrimer); L is one or more linking moieties or spacers; X is a radionuclide or a chelator for complexing with a radionuclide or an MRI contrast agent; n is an integer from 1 to 100; and m is an integer from 16 to 4096; Y is a linker selected from secondary amide (-CONH-), tertiary amide (-CONR-), sulfonamide (-S(O)2-NR-), secondary carbamate (-OCONH-; -NHCOO-), tertiary carbamate (-OCONR-; -NRCOO-), carbonate (-OC(O)-O-), urea (-NHCONH-; -NRCONH-; -NHCONR-, -NRCONR-), carbinol (-CHOH-, -CROH-), disulfide group, hydrazone, hydrazide, thioether (-S-, -SR-), and ether (-O-, -OR-), where R is an alkyl group, an aryl group, or a heterocyclic group. In some embodiments, Y is a bond or linkage that is resistant to cleavage in vivo. In some embodiments, Y is a C1-C6 12 , for example, a C1-C6 alkyl group, or a polyethylene glycol linker.
[0064] In one embodiment, D is a G4 PAMAM dendrimer; L is one or more linking or spacer moieties; and R is 18 F; n is about 8 to 12; m is an integer from about 52 to 56; and n+m=64. In some embodiments, L is C1 to C 12 It includes an alkyl group, such as a C1-C6 alkyl group, or a polyethylene glycol linker.
[0065] In another embodiment, D is a G4 PAMAM dendrimer; L is one or more linking or spacer moieties; R is p-SCN-Bn-deferoxamine; n is about 8-12; m is an integer between about 52 and 56; and n+m=64.
[0066] i. Chelation Agent In some embodiments, one or more radionuclides are conjugated to the dendrimer via a chelating agent. Metallic radionuclides can be chelated by, for example, linear, macrocyclic, terpyridine, and N3S, N2S2, or N4 complexing agents (see also U.S. Pat. Nos. 5,367,080, 5,364,613, 5,021,556, 5,075,099, and 5,886,142), as well as other chelators known in the art, including, but not limited to, HYNIC, DTPA, EDTA, DOTA, DO3A, TETA, NOTA, and bisaminobisthiol (BAT) chelators (see also U.S. Pat. No. 5,720,934). For example, N4 chelators are described in U.S. Patent Nos. 6,143,274; 6,093,382; 5,608,110; 5,665,329; 5,656,254; and 5,688,487. 35 Chelators are described in PCT / CA94 / 00395, PCT / CA94 / 00479, PCT / CA95 / 00249, and U.S. Patent No. 5,662,885; U.S. Patent No. 5,976,495; and U.S. Patent No. 5,780,006.Chelators can also include mercapto-acetyl-acetyl-glycyl-glycine (MAG3) containing N3S, which is a chelating ligand derivative, and N2S2 systems, such as MAMA (monoamide monoamine dithiol), DADS (N2S diamine dithiol), and CODADS.These and various other ligand systems are described, for example, in Liu, S, and Edwards, D., 1999. Chem. Rev., 99:2235-2268, and references therein.
[0067] Chelators can also include complexes containing ligand atoms that are not donated to the metal in a tetradentate array. These include, for example, the boronic acid adducts of technetium and rhenium dioximes described in U.S. Patent Nos. 5,183,653; 5,387,409; and 5,118,797, the disclosures of which are incorporated herein by reference in their entireties.
[0068] In one embodiment, the chelator is 89 p-SCN-Bn-deferoxamine (DFO) for chelating Zr. In another embodiment, the chelator is 90 DOTA for chelating Y and / or Gd.
[0069] The chelator can be covalently linked to the dendrimer, optionally via a linker, and then directly labeled with a radionuclide or MRI contrast agent. In some embodiments, the dendrimer is conjugated to the chelator through an ether linkage, with or without a linker, for enhanced stability. 18 F, 89 Dendrimers containing Zr (zirconium-89) or Gd are provided herein for diagnostic imaging. Radioactive technetium complexes are also useful for diagnostic imaging, and radioactive rhenium complexes are particularly useful for radiotherapy.
[0070] ii. Fluorine-18 / dendrimer conjugates In some embodiments, the dendrimer is 18 It is conjugated to F (fluorine-18). 18 F (fluorine-18) is the most commonly used isotope for PET imaging. It is an isotope of fluorine with a high positron decay rate, low energy, a favorable half-life (109.8 minutes), high specific activity, and well-established radiochemistry. It decays by emitting a positron with the lowest positron energy, contributing to the acquisition of high-resolution images. 18F radiotracers, such as the glucose analog 2-deoxy-2-F-fluoro-β-D-glucose (F-FDG), have been approved by the FDA for clinical applications and are used for the early detection of tumors. Thus, in some embodiments, the radionuclide conjugated to the hydroxyl-terminated dendrimer via an ether linkage is 18 F. via an ether linkage 18 An exemplary hydroxyl-terminated dendrimer conjugated to F is shown in FIG.
[0071] iii. Zirconium-89 / dendrimer conjugate In some embodiments, the dendrimer is 89 It is conjugated to Zr (zirconium-89). 89 Zr is another PET isotope with a long half-life (78.4 hours) that matches the pharmacokinetics of antibodies, and has a relatively low mean positron energy of 395 keV. 89 Zr-based radiotracers are good candidates for clinical applications because they are safer to handle and more stable in vivo. Thus, in some embodiments, the radionuclide conjugated to the hydroxyl-terminated dendrimer via an ether linkage is 89 Zr. via ether linkage 89 An exemplary hydroxyl-terminated dendrimer conjugated to Zr is shown in FIG.
[0072] iv. Yttrium-90 / dendrimer conjugate In some embodiments, the dendrimer is 90 It is conjugated to Y (yttrium-90). 90 Y is an isotope of yttrium. 90 Y is a pure beta emitter with a mean decay energy of 0.93 MeV and a mean penetration depth in human tissue of 4-5 mm. The physical half-life of Y-90 is 64.2 hours. Yttrium-90 has found widespread use in radiation therapy to treat some forms of cancer.
[0073] Thus, in some embodiments, the radionuclide conjugated to the hydroxyl-terminated dendrimer via an ether linkage is 90 Y. Conjugated to DOTA via an ether linkage, 90 An exemplary hydroxyl-terminated dendrimer chelated with Y is shown in Figure 5. Alternatively, Gd may be chelated with this hydroxyl-terminated dendrimer-DOTA conjugate. For cancer treatment, the dendrimer labeled with one or more radionuclides can be further conjugated to one or more anti-cancer drugs. An exemplary structure of a dendrimer labeled with one or more radionuclides further conjugated to one or more anti-cancer drugs is shown in Figure 6.
[0074] Spacers and Linkers In some embodiments, attachment of the imaging or diagnostic agent to the dendrimer occurs via one or more of a disulfide, ether, thioester, carbamate, carbonate, hydrazine, or amide linkage. In some embodiments, attachment occurs via an appropriate spacer that provides an ether or amide bond between the radionuclide and the dendrimer, depending on the desired release kinetics of the active agent. One or more spacers / linkers between the dendrimer and the radionuclide can be designed to provide a non- or negligible form of the dendrimer / agent conjugate in vivo. In some embodiments, an ether bond is introduced to provide a non- or negligible form of the dendrimer conjugate. Additionally, one or more organic functional groups can be selected to facilitate covalent attachment of the active agent to the dendrimer / agent conjugate.
[0075] The linking moiety generally comprises one or more organic functional groups. Examples of suitable organic functional groups include secondary amide (-CONH-), tertiary amide (-CONR-), sulfonamide (-S(O)-NR-), secondary carbamate (-OCONH-; -NHCOO-), tertiary carbamate (-OCONR-; -NRCOO-), carbonate (-OC(O)-O-), urea (-NHCONH-; -NRCONH-; -NHCONR-, -NRCONR-), carbinol (-CHOH-, -CROH-), disulfide group, hydrazone, hydrazide, ether (-O-), and ester (-COO-, -CHOC-, -CHROC-) (wherein R is an alkyl group, an aryl group, or a heterocyclic group).
[0076] In certain embodiments, the linking moiety comprises one or more of the above organic functional groups in combination with a spacer group. The spacer group can be composed of any assembly of atoms, including oligomeric and polymeric chains; however, the total number of atoms in the spacer group is between 3 and 200 atoms, between 3 and 150 atoms, between 3 and 100 atoms, or between 3 and 50 atoms. Examples of suitable spacer groups include alkyl groups, heteroalkyl groups, alkylaryl groups, oligo- and polyethylene glycol chains, and oligo- and poly(amino acid) chains. Variations in the spacer group provide additional control over the release of the agent in vivo. In embodiments in which the linking group comprises a spacer group, one or more organic functional groups are typically used to connect the spacer group to both the radionuclide and the dendrimer. In some embodiments, the spacer is polyethylene glycol.
[0077] Compositions and methods for conjugating agents to dendrimers are known in the art and are described in detail in U.S. Patent Application Publication Nos. 2011 / 0034422, 2012 / 0003155, and 2013 / 0136697. In some embodiments, the active agent is functionalized for conjugation to the dendrimer / agent conjugate, optionally via one or more linking moieties. In some embodiments, the functionalized active agent and / or linking moiety are designed to have a desired release rate of the active agent from the dendrimer / agent conjugate in vivo. The functionalized active agent and / or linking moiety can be designed to be cleaved hydrolytically, enzymatically, or a combination thereof to provide sustained release of the active agent in vivo. In some embodiments, the functionalized active agent and / or linking moiety are designed to remain bound to the dendrimer / agent conjugate in vivo.
[0078] Thus, in some embodiments, the functionalized active agent and / or linking moiety are designed to cleave at a minimal or inconsequentially low rate in vivo. The composition of the linking moiety can also be selected taking into account the desired release rate of the active agent. In some embodiments, one or more active agents are functionalized to be non-cleavable or substantially non-cleavable from the dendrimer / agent conjugate in vivo, e.g., via an ether linkage, optionally with one or more spacers / linkers.
[0079] Optimal loading of imaging agents, such as radionuclides, necessarily depends on many factors, including the choice of radionuclide, the structure and size of the dendrimer, and the tissue to be targeted / imaged. In some embodiments, one or more imaging agents are encapsulated, associated with, and / or conjugated to the dendrimer at concentrations of about 0.01% to about 45% by weight, about 0.1% to about 30% by weight, about 0.1% to about 20% by weight, about 0.1% to about 10% by weight, about 1% to about 10% by weight, about 1% to about 5% by weight, about 3% to about 20% by weight, and about 3% to about 10% by weight. However, optimal loading of any imaging agent, dendrimer, and targeting moiety can be identified by routine methods, such as those described.
[0080] In some embodiments, conjugation of the imaging agent and / or linker occurs through one or more surface and / or internal groups. Thus, in some embodiments, conjugation of the active agent / linker occurs through about 1%, 2%, 3%, 4%, or 5% of the total surface functional groups, e.g., hydroxyl groups, of the dendrimer / agent available prior to conjugation. In other embodiments, conjugation of the active agent / linker occurs on less than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75% of the total surface functional groups of the dendrimer available prior to conjugation. In some embodiments, the dendrimer / agent complex retains an effective amount of surface functional groups for targeting a particular cell type, but is conjugated to an effective amount of an active agent for treating, preventing, and / or imaging a disease or disorder.
[0081] In some aspects, the present disclosure provides compounds comprising a dendrimer conjugated to one or more agents (e.g., imaging agents, therapeutic agents) through terminal ester, ether, or amide bonds. In some embodiments, the dendrimer comprises surface (e.g., terminal) hydroxyl groups, optionally substituted with agents. As used herein, in some embodiments, a dendrimer conjugate refers to a compound comprising a dendrimer conjugated to one or more agents. In some embodiments, a dendrimer conjugate comprises a dendrimer conjugated to an imaging agent. In some embodiments, a dendrimer conjugate comprises a dendrimer conjugated to an imaging agent or a therapeutic agent. In some embodiments, a dendrimer conjugate comprises a dendrimer conjugated to an imaging agent and a therapeutic agent.
[0082] In some aspects, the present disclosure provides compositions comprising a compound comprising a dendrimer conjugated to an agent (e.g., an imaging agent and / or a therapeutic agent) through a terminal ester, ether, or amide bond. In some embodiments, the dendrimer comprises a high density of terminal hydroxyl groups, optionally substituted with an agent. In some embodiments, the compound comprising a dendrimer conjugated to an agent comprises 10-20% by weight of the agent. In some embodiments, the terminal ester, ether, or amide bond is conjugated to the agent through a linker or spacer. In some embodiments, the dendrimer is conjugated to the agent through a terminal ether bond. In some embodiments, the compound comprises about 10% to about 15% by weight of the agent. In some embodiments, the compound comprises about 15% to about 20% by weight of the agent. In some embodiments, at least 50% of the terminal sites on the dendrimer comprise terminal hydroxyl groups. In some embodiments, at least 50% and up to 99% (e.g., 50-95%, 50-90%, 50-80%, 50-70%, 50-60%, 60-80%, 70-90%) of the terminal sites in the dendrimer comprise terminal hydroxyl groups.
[0083] In some embodiments, the agent (e.g., imaging agent or therapeutic agent) of the compounds described herein has increased aqueous solubility compared to the unconjugated compound comprising the agent in the absence of the dendrimer. In some embodiments, the aqueous solubility is increased by at least 10% compared to the unconjugated compound. In some embodiments, the aqueous solubility is increased by between about 10% and about 100% compared to the unconjugated compound. In some embodiments, the aqueous solubility is increased by at least about two-fold compared to the unconjugated compound. In some embodiments, the aqueous solubility is increased by between about two-fold and about ten-fold compared to the unconjugated compound. In some embodiments, the aqueous solubility is solubility under physiological conditions. In some embodiments, the aqueous solubility is solubility in water having a pH between about 7.0 and about 8.0. In some embodiments, the imaging agent is present at a concentration at which the unconjugated compound is insoluble under physiological conditions.
[0084] In some embodiments, the surface functional groups (e.g., terminal functional groups) of the dendrimer comprise one or more hydroxyl groups, one or more amine groups, and / or one or more carboxyl groups. In some embodiments, the terminal functional groups of the dendrimer provide attachment sites through which at least one agent (e.g., an imaging agent and / or a therapeutic agent) is conjugated to form a dendrimer conjugate. Thus, in some embodiments, at least one agent is conjugated to the dendrimer through an ether, amide, or ester bond formed by conjugation to the terminal functional group of the dendrimer. In some embodiments, at least one agent is conjugated to the dendrimer through an ether or amide bond. In some embodiments, at least one agent is conjugated to the dendrimer through an ether bond.
[0085] In some embodiments, the number of terminal moieties in a dendrimer can depend on the particular dendrimer scaffold and its generation. For example, in some embodiments, the dendrimer is based on a generation 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 PAMAM dendrimer scaffold, with 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, and 4096 terminal moieties, respectively. However, it should be understood that different dendrimer scaffolds with different numbers of terminal moieties in each generation can be used in accordance with the present disclosure.
[0086] In some embodiments, all terminal moieties of the dendrimer comprise hydroxyl groups. In some embodiments, each terminal moiety of the dendrimer comprises either a hydroxyl group or an amine group. In some embodiments, each terminal moiety of the dendrimer conjugate comprises either a hydroxyl group, an amine group, or an agent (e.g., an imaging agent or a therapeutic agent) conjugated to the dendrimer through an ether or amide bond. In some embodiments, each terminal moiety of the dendrimer conjugate comprises either a hydroxyl group or an agent conjugated to the dendrimer through an ether bond.
[0087] In some embodiments, at least 50% of the terminal sites on the dendrimer conjugate comprise hydroxyl groups (e.g., at least 50% of the terminal sites comprise neither amine groups nor agents). For example, in some embodiments, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% of the terminal sites on the dendrimer conjugate comprise hydroxyl groups. In some embodiments, about 50-99%, about 60-99%, about 70-99%, about 80-99%, about 90-99%, about 95-99%, about 98-99%, about 70-95%, about 70-90%, about 80-95%, or about 80-90% of the terminal sites on the dendrimer conjugate comprise hydroxyl groups.
[0088] In some embodiments, one or more terminal moieties in the dendrimer conjugate comprise an agent (e.g., an imaging agent and / or a therapeutic agent). In some embodiments, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, or more terminal moieties in the dendrimer conjugate comprise an agent. In some embodiments, at least 1% of the terminal moieties in the dendrimer conjugate comprise an agent. For example, in some embodiments, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, or at least 30% of the terminal moieties in the dendrimer conjugate comprise an agent. In some embodiments, about 1-50%, about 1-40%, about 1-25%, about 1-10%, about 5-50%, about 5-40%, about 5-25%, about 5-10%, about 10-50%, about 10-40%, or about 10-25% of the terminal sites on the dendrimer conjugate comprise an agent. In some embodiments, about 1%, about 2%, about 3%, about 4%, or about 5% of the terminal sites on the dendrimer comprise an agent. In some embodiments, less than 5%, less than 10%, less than 15%, less than 20%, less than 25%, less than 30%, less than 35%, less than 40%, less than 45%, less than 50%, less than 55%, less than 60%, less than 65%, less than 70%, or less than 75% of the terminal sites on the dendrimer comprise an agent. In some embodiments, the dendrimer conjugate has an effective amount of terminal functional groups (e.g., terminal hydroxyl groups) for targeting a particular cell type while having an effective amount of an agent for imaging and / or treating as described herein. In some embodiments, the terminal moieties of the dendrimer conjugate are subjected to proton nuclear magnetic resonance (NMR) analysis as known in the art to determine the percentage of terminal moieties bearing an agent and / or terminal functional group. 1 1 H NMR), or other analytical methods.
[0089] In some embodiments, the desired agent loading may depend on certain factors, including the choice of agent, the structure and size of the dendrimer, and the cell or tissue to be treated. In some embodiments, the dendrimer conjugate is about 0.01% to about 45% (m / m) of the agent (e.g., imaging agent and / or therapeutic agent) by weight. In some embodiments, the dendrimer conjugate is about 10% to about 20% of the agent by weight. In some embodiments, the dendrimer conjugate is about 0.1% to about 30%, about 0.1% to about 20%, about 0.1% to about 10%, about 1% to about 10%, about 1% to about 5%, about 3% to about 20%, or about 3% to about 10% of the agent by weight.
[0090] As described herein, in some embodiments, a dendrimer conjugate can be characterized in terms of the mass percentage (e.g., mass % (m / m)) of the agent. In some embodiments, the mass percentage refers to the molecular weight (Da) percentage of the agent in the dendrimer conjugate. In some embodiments, the mass percentage can be expressed by the general formula: (agent M W ) / (Conjugate M W ) × 100. For example, in some embodiments, W ) can be determined by calculating or estimating the molecular weight of the agent as a single molecule or compound (conjugated or unconjugated) and multiplying this value by the number of terminal moieties at which the agent is present on the dendrimer conjugate. In some embodiments, (agent M W ) can be determined by calculating or estimating the sum of the atomic masses of all atoms that form the agent in the dendrimer conjugate. W ) values are calculated for the dendrimer conjugate (conjugate M W) and multiplied by 100 to provide the mass percentage. In some embodiments, the mass percentage can be determined by experimental or empirical means. For example, in some embodiments, the mass percentage can be determined by proton nuclear magnetic resonance ( 1 1 H NMR) or other analytical methods known in the art.
[0091] In some embodiments, attachment of the dendrimer to the active agent occurs via a suitable spacer that provides an ether bond between the agent and the dendrimer / agent. In some embodiments, one or more spacers / linkers are added between the dendrimer and the active agent to achieve desired and effective binding and / or pharmacokinetics in vivo.
[0092] The spacer can be either a single chemical entity or two or more chemical entities linked together to bridge the polymer and the therapeutic or imaging agent. Spacers can include sulfhydryl, thiopyridine, succinimidyl, maleimide, vinyl sulfone, and any small chemical entity, peptide, or polymer with a carbonate terminus.
[0093] The spacer can be selected from the classes of compounds terminated with sulfhydryl, thiopyridine, succinimidyl, maleimide, vinyl sulfone, and carbonate groups. The spacer can include a thiopyridine-terminated compound, such as dithiodipyridine, N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP), succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate LC-SPDP, or Sulfo-LC-SPDP. The spacer may also include peptides that are essentially linear or cyclic and have sulfhydryl groups, such as glutathione, homocysteine, cysteine, and their derivatives, such as arg-gly-asp-cys (RGDC), cyclo(Arg-Gly-Asp-d-Phe-Cys) (c(RGDfC)), cyclo(Arg-Gly-Asp-d-Tyr-Cys), and cyclo(Arg-Ala-Asp-d-Tyr-Cys). The spacer may also be a mercapto acid derivative, such as 3-mercaptopropionic acid, mercaptoacetic acid, 4-mercaptobutyric acid, thiolan-2-one, 6-mercaptohexanoic acid, 5-mercaptovaleric acid, and other mercapto derivatives, such as 2-mercaptoethanol and 2-mercaptoethylamine. The spacer can be thiosalicylic acid and its derivatives, (4-succinimidyloxycarbonyl-methyl-alpha-2-pyridylthio)toluene, (3-[2-pyridithio]propionyl hydrazide. The spacer can be maleimide-terminated. Spacers include polymers or small molecule chemical entities such as bismaleimide diethylene glycol and bismaleimide triethylene glycol, bismaleimide ethane, and bismaleimide hexane. The spacer can include vinyl sulfones, such as 1,6-hexane-bis-vinyl sulfone. The spacer can include thioglycosides, such as thioglucose. The spacer can be reduced proteins such as bovine serum albumin and human serum albumin, or any thiol-terminated compound capable of forming a disulfide bond. The spacer can include maleimide, succinimidyl, and thiol-terminated polyethylene glycol.
[0094] Formulations for nuclear imaging (radionuclide imaging) and radiation therapy In some embodiments, dendrimers conjugated to one or more diagnostic or imaging agents containing radionuclides are formulated for use in nuclear imaging (radionuclide imaging) and radiotherapy techniques. In some embodiments, the unit dose administered has a radioactivity of about 0.01 mCi to about 100 mCi, or about 1 mCi to about 20 mCi. In some embodiments, the solution injected in a unit dosage is about 0.01 mL to about 10 mL. In some embodiments, the dendrimer conjugate can be formed as a radioconjugate in a solution containing radioactivity at a concentration of about 0.01 mCi to 100 mCi / mL.
[0095] In some embodiments, a dose of radionuclide-labeled dendrimer can provide 10-20 mCi. In some embodiments, after injection of the radionuclide-labeled dendrimer into a patient, a gamma camera calibrated for the gamma-ray energy of the nuclide incorporated into the imaging agent is used to image the area of agent uptake and quantify the amount of radioactivity present at the site. Imaging of the site in vivo can be performed in just a few minutes. However, imaging can be performed several hours or longer, if desired, after administration of the radiolabeled dendrimer composition to the patient. In some embodiments, a sufficient amount of the administered dose accumulates in the area to be imaged within about 0.1 of an hour to allow for scintiphotography.
[0096] Suitable dosing schedules for the radiotherapy compounds of the present disclosure are known to those skilled in the art. The compounds can be administered using a number of methods, including, but not limited to, one or more IV or IP injections, using a quantity of radioactivity sufficient to cause targeted tissue damage or ablation, but not so great as to cause substantial damage to non-target (normal) tissue. The required amount and dose will vary for different constructs depending on the energy and half-life of the isotope used, the degree of uptake and excretion of the agent from the body, and the mass of the target tissue. Generally, doses can range from a single dose of about 30-50 mCi, up to a cumulative dose of up to about 3 Ci.
[0097] Radiotherapeutic compositions may include physiologically acceptable buffers and may require radiostabilizers to prevent radiolytic damage to the compound prior to injection. Radiostabilizers are known to those skilled in the art and may include, for example, para-aminobenzoic acid, ascorbic acid, gentisic acid, etc.
[0098] Additional activators In some embodiments, dendrimers complexed or conjugated with one or more radionuclides are further conjugated to one or more active agents. Exemplary additional active agents include therapeutic, prophylactic, or diagnostic agents.
[0099] Dendrimers have the advantage of being able to deliver multiple therapeutic, prophylactic, and / or diagnostic agents within the same dendrimer. Thus, one or more types of active agents can be encapsulated, complexed, or conjugated to the dendrimer / imaging agent. In one embodiment, the dendrimer / imaging agent complexes or conjugates with two or more different classes of active agents, providing simultaneous delivery with different or independent release kinetics at the target site. The included active agents can be proteins or peptides, sugars or carbohydrates, nucleic acids or oligonucleotides, lipids, or small molecules (e.g., molecular weights less than 2,500 daltons, less than 2,000 daltons, or less than 1,500 daltons). The nucleic acid can be an oligonucleotide encoding a protein, such as a DNA expression cassette or mRNA. Representative oligonucleotides include siRNA, microRNA, DNA, and RNA. In some embodiments, the additional active agent is a therapeutic antibody.
[0100] For example, in some embodiments, the dendrimer / imaging agent is covalently linked to at least one additional detectable moiety and / or at least one agent of another class, hi further embodiments, dendrimer / imaging agent complexes, each with an additional agent of a different class, are administered simultaneously for combination treatment.
[0101] The selective targeting of dendrimers allows for the administration of less active agent to achieve the same therapeutic effect compared to the same active agent not conjugated to a dendrimer, thus reducing the dose-related cytotoxicity and / or other side effects associated with the active agent. Dendrimers can also increase the solubility of one or more additional therapeutic, prophylactic, and / or diagnostic agents to be delivered. Examples of additional active agents include therapeutic agents that have been shown to be effective in treating and preventing one or more inflammatory diseases or disorders or cancer.
[0102] In some embodiments, the additional active agent is a diagnostic agent. Useful additional diagnostic agents include moieties that can be administered in vivo and subsequently detected. The additional agent can be, for example, any moiety that facilitates detection directly or indirectly by non-invasive and / or in vivo visualization techniques. Examples of additional diagnostic agents include paramagnetic molecules, fluorescent compounds, magnetic molecules, x-ray imaging agents, and contrast media. Other suitable contrast agents include radiopaque gases or gas-releasing compounds. In some embodiments, the dendrimer complex further comprises an agent useful for determining the location of the administered composition, such as a fluorescent tag and an imaging agent. Exemplary diagnostic agents include dyes, fluorescent dyes, near-infrared dyes, fluorescent molecules (also known as fluorescent dyes and fluorophores), chemiluminescent agents (e.g., luminol), bioluminescent agents (e.g., luciferin and green fluorescent protein (GFP)), metals (e.g., gold nanoparticles), and radioisotopes. Suitable detectable labels can be selected based on the imaging method chosen. For example, in some embodiments, the additional detectable label is a near-infrared fluorescent dye for optical imaging, a gadolinium chelate for MRI imaging, or a gold nanoparticle for CT imaging.
[0103] In some embodiments, the additional agent is both an imaging agent and a diagnostic agent, and / or a therapeutic agent. In some embodiments, the additional agent is a tantalum compound, an organic iodo acid such as iodocarboxylic acid, triiodophenol, iodoform, and / or tetraiodoethylene, a non-radioactive detectable agent such as a non-radioactive isotope such as iron oxide and Gd, an enzyme, a fluorophore, and a quantum dot (QDOT®), Lissamine rhodamine PE, for example, a fluorescent or non-fluorescent dye or pigment that can impart a visible color or reflect a characteristic spectrum of electromagnetic radiation at visible or other wavelengths, such as infrared or ultraviolet, e.g., rhodamine, a ferromagnetic compound, a paramagnetic compound such as gadolinium, a superparamagnetic compound such as iron oxide, and a diamagnetic compound such as barium sulfate.
[0104] In some embodiments, the one or more additional active agents are functionalized, e.g., via an ether or amide linkage, optionally with one or more spacers / linkers, to facilitate conjugation to the dendrimer for desired release kinetics. In some embodiments, the one or more additional active agents are functionalized, e.g., via an ether, optionally with one or more spacers / linkers, to be non-cleavable or substantially non-cleavable in vivo from the dendrimer conjugate. In other embodiments, the one or more additional active agents delivered via the dendrimer conjugate are released from the dendrimer complex for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, at least 1 week, 2 weeks, or 3 weeks, or at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months after administration to a mammalian subject in an amount effective to be therapeutically effective in the target cell, tissue, or region.
[0105] The agent and / or targeting moiety may be covalently attached, dispersed intramolecularly, or encapsulated in the dendrimer conjugate. In some embodiments, the dendrimer conjugated to one or more radionuclides or MRI contrast agents is a hydroxyl-terminated up to 10th generation dendrimer, such as a PAMAM dendrimer.
[0106] Methods for Making Dendrimer / Agent Conjugates In some aspects, the present disclosure provides methods for making dendrimers complexed or conjugated with one or more imaging or diagnostic agents. The methods conjugate the dendrimers with one or more radionuclide reporters suitable for scintigraphy, SPECT, or PET imaging, one or more MRI contrast agents, and / or one or more radionuclides suitable for radiotherapy. Methods for making dendrimer complexes in which the dendrimer is conjugated with a first radionuclide useful for diagnostic imaging and a second radionuclide useful for radiotherapy are specifically contemplated; in some embodiments, conjugation to the first and / or second radionuclide (or suitable chelators for the first and / or second radionuclide) is via an ether linkage. Thus, in some embodiments, a single dendrimer / radionuclide composition can simultaneously treat and / or diagnose a disease or condition at one or more locations in the body. Similarly, radiolabeled SPECT or scintigraphy imaging agents with suitable amounts of radioactivity are also disclosed.
[0107] Methods for Making Dendrimers Dendrimers can be purchased or prepared through a variety of chemical reaction steps. Dendrimers are usually synthesized according to methods that allow control of their structure at every stage of construction. Dendritic structures are often synthesized by two main different approaches: divergent and convergent.
[0108] Methods for producing dendrimers are known to those skilled in the art and generally involve a two-step iterative reaction sequence that produces concentric shells (generations) of dendritic β-alanine units around a central starting core (e.g., an ethylenediamine core). Each subsequent growth step represents a new "generation" of polymer with a larger molecular diameter, twice the number of reactive surface sites, and approximately double the molecular weight of the previous generation. Dendrimer scaffolds suitable for use are commercially available in various generations. In some embodiments, the dendrimer composition is based on a generation 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 dendrimer scaffold. Such scaffolds have 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, and 4096 reactive sites, respectively. Thus, dendrimer compounds based on these scaffolds can have a maximum corresponding number of agents or moieties attached thereto, either directly or indirectly through linkers.
[0109] In some embodiments, dendrimers are prepared using different methods in which dendrimers are assembled from a multifunctional core, which is then extended outward through a series of reactions, typically a Michael reaction. The strategy involves coupling monomer molecules bearing reactive and protecting groups to the multifunctional core moiety, resulting in the stepwise addition of generations around the core, followed by removal of the protecting groups. For example, PAMAM-NH2 dendrimers are first synthesized by coupling N-(2-aminoethyl)acrylamide monomers to an ammonia core.
[0110] In other embodiments, dendrimers are prepared using convergent methods, where the dendrimer is built from small molecules that terminate at the surface of a sphere and the reaction proceeds inward, building inwards and ultimately attaching to the core.
[0111] Many other synthetic routes exist for the preparation of dendrimers, such as the orthogonal approach, the accelerated approach, the double-stage convergent method, or hypercore approach, the hypermonomer method, or branched monomer approach, the double exponential method, the orthogonal coupling method, or two-stage approach, the two-monomer approach, the AB2-CD2 approach.
[0112] In some embodiments, the dendrimer core, one or more branching units, one or more linker / spacer, and / or one or more surface groups can be modified to enable conjugation to additional functional groups (branching units, linkers / spacers, surface groups, etc.), monomers, and / or active agents via click chemistry using one or more of copper-assisted azide-alkyne cycloaddition (CuAAC), Diels-Alder reaction, thiol-ene and thiol-yne reactions, and azide-alkyne reactions (Arseneault M et al., Molecules. 2015 May 20;20 (5):9263-94). In some embodiments, prefabricated dendrons are clicked onto the high-density hydroxyl polymer. "Click chemistry" involves the coupling of two different moieties (e.g., a core group and a branching unit; or a branching unit and a surface group) via a 1,3-dipolar cycloaddition reaction between, for example, an alkyne moiety (or its equivalent) on the surface of a first moiety and an azide moiety (e.g., present in a triazine composition, or its equivalent) or any active end group (e.g., primary amine end group, hydroxyl end group, carboxylic acid end group, thiol end group, etc.) of a second moiety.
[0113] In some embodiments, dendrimer synthesis relies on one or more reactions, such as thiol-ene click reaction, thiol-yne click reaction, CuAAC, Diels-Alder click reaction, azide-alkyne click reaction, Michael addition, epoxy ring-opening, esterification, silane chemistry, and combinations thereof.
[0114] Any existing dendritic platform can be used to create dendrimers with the desired functionality, i.e., a high density of surface hydroxyl groups, by conjugating high-hydroxyl-containing moieties, such as 1-thio-glycerol or pentaerythritol. Exemplary dendritic platforms can be synthesized and explored, such as polyamidoamine (PAMAM), poly(propyleneimine) (PPI), poly-L-lysine, melamine, poly(etherhydroxylamine) (PEHAM), poly(esteramine) (PEA), and polyglycerol.
[0115] Dendrimers can also be prepared by combining two or more dendrons. A dendron is the wedge-shaped portion of a dendrimer that contains a reactive focal point functional group. Many dendron scaffolds are commercially available. They fall into the first, second, third, fourth, fifth, and sixth generation, with 2, 4, 8, 16, 32, and 64 reactive groups, respectively. In certain embodiments, one type of activator is linked to one type of dendron, and a different type of activator is linked to another type of dendron. The two dendrons are then connected to form a dendrimer. The two dendrons can be linked via click chemistry, i.e., a 1,3-dipolar cycloaddition reaction, between an azide moiety on one dendron and an alkyne moiety on another dendron to form a triazole linker.
[0116] Exemplary methods of making dendrimers are described in detail in International Patent Publications WO2009 / 046446, WO2015168347, WO2016025745, WO2016025741, WO2019094952, and U.S. Pat. No. 8,889,101.
[0117] Dendrimer conjugates with radionuclides and / or MRI contrast agents Methods for preparing dendrimer complexes with one or more radionuclides or MRI contrast agents are described.Methods for conjugating agents to dendrimers are known in the art and are described in detail in U.S. Patent Application Publication Nos. 2011 / 0034422, 2012 / 0003155, and 2013 / 0136697.
[0118] Reactions and strategies useful for covalently attaching active agents to dendrimers are known in the art. See, for example, March, "Advanced Organic Chemistry," 5th Edition, 2001, Wiley-Interscience Publication, New York) and Hermanson, "Bioconjugate Techniques," 1996, Elsevier Academic Press, USA. The appropriate method for covalently attaching a given active agent can be selected based on the desired linking moiety and the overall agent and dendrimer structure in relation to functional group compatibility, protecting group strategy, and the presence of labile bonds.
[0119] Conjugation of dendrimers to radionuclides or MRI contrast agents via ether linkages Similarly, methods are provided for incorporating radionuclides and / or MRI contrast agents into hydroxyl-terminated dendrimers via ether linkages, optionally via one or more linkers / spacers.
[0120] In some embodiments, the surface or terminal groups of the hydroxyl-terminated dendrimer are modified via an etherification reaction prior to conjugation to one or more linkers / spacers and one or more active agents (e.g., radionuclides or MRI contrast agents). Etherification is the dehydration of an alcohol to form an ether. In some embodiments, one or more hydroxyl groups of the hydroxyl-terminated dendrimer undergo an etherification reaction prior to conjugation to one or more linking moieties and one or more active agents.
[0121] In one embodiment, ether linkages are introduced to the surface groups of hydroxyl PAMAM dendrimers by reaction with propargyl bromide in the presence of 2% sodium hydroxide solution in DMSO (FIG. 1) as described in Example 1. In a further embodiment, the etherification reaction of the fourth generation hydroxyl-terminated PAMAM dendrimer, PAMAM-G4-OH, using allyl bromide, anhydrous cesium carbonate, and tetrabutylammonium iodide in DMF is described in Example 3, and the reaction scheme is shown in FIG.
[0122] Exemplary synthetic routes are shown in FIGS. 18 F was conjugated to a hydroxyl-terminated fourth-generation PAMAM dendrimer shown as compound 5 in Figure 1 ; 89 Zr forms a complex with the hydroxyl-terminated fourth generation PAMAM dendrimer via chelation through p-SCN-Bn-deferoxamine (DFO) conjugated to the dendrimer, shown as compound 5 in Figure 3 .
[0123] Pharmaceutical preparations Pharmaceutical compositions containing dendrimers conjugated to one or more radionuclides and / or one or more MRI contrast agents, and optionally one or more active agents, can be formulated in a conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliary agents that facilitate the processing of the active compounds into pharmaceutically usable preparations. The appropriate formulation depends on the selected route of administration. In some embodiments, the composition is formulated for parenteral delivery. In some embodiments, the composition is formulated for subcutaneous injection. Typically, the composition is formulated in a sterile saline or buffer solution for injection into the tissue or cells to be treated. The composition can be lyophilized and stored in single-use vials for rewetting immediately before use. Other means of rewetting and administration are known to those skilled in the art.
[0124] Pharmaceutical formulations contain one or more dendrimer / agent conjugates in combination with one or more pharmaceutically acceptable excipients. Representative excipients include solvents, diluents, pH modifiers, preservatives, antioxidants, suspending agents, wetting agents, viscosity adjusters, tonicity agents, stabilizers, and combinations thereof. In some embodiments, suitable pharmaceutically acceptable excipients are selected from materials that are generally recognized as safe (GRAS) and can be administered to individuals without causing undesirable biological side effects or unwanted interactions. See, for example, Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, MD, 2000, p. 704.
[0125] In some embodiments, the compositions are formulated in dosage unit form for ease of administration and uniformity of dosage. The phrase "dosage unit form" refers to a physically discrete unit of the conjugate appropriate for the patient being treated. However, it will be understood that the total single administration of the composition will be determined by the attending physician within the scope of sound medical judgment. A therapeutically effective dose can be initially estimated either in cell culture assays or animal models, usually mice, rabbits, dogs, or pigs. Animal models are also used to achieve a desirable concentration range and route of administration. Such information should then be useful for determining useful doses and routes of administration in humans. The therapeutic efficacy and toxicity of the conjugates can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic effects to therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50 / ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies can be used to formulate a range of dosage for use in humans.
[0126] Pharmaceutical compositions formulated for administration by parenteral (intramuscular, intraperitoneal, intravenous, or subcutaneous injection) and enteral routes of administration are described.
[0127] Parenteral administration The phrases "parenteral administration" and "administered parenterally" are art-recognized terms and include modes of administration other than enteral and topical administration, such as injection, including, but not limited to, intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal injection and infusion. Dendrimer compositions may be administered parenterally, for example, by subdural, intravenous, intrathecal, intraventricular, intraarterial, intraamniotic, intraperitoneal, or subcutaneous routes. In some embodiments, the dendrimer compositions are administered via subcutaneous injection.
[0128] For liquid formulations, pharmaceutically acceptable carriers can be, for example, aqueous or non-aqueous solutions, suspensions, emulsions, or oils. Parenteral vehicles (for subcutaneous, intravenous, intraarterial, or intramuscular injection) include, for example, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, cyclodextrins, emulsions, or suspensions, including, for example, saline and buffered media. The dendrimer composition can also be administered in emulsions, such as water-in-oil emulsions. Examples of oils include oils of petroleum, animal, vegetable, or synthetic origin, petrolatum, and mineral oils. Suitable fatty acids for use in parenteral formulations include, for example, oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
[0129] Suitable formulations for parenteral administration may include aqueous and non-aqueous sterile suspensions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, as well as suspending agents, solubilizers, thickeners, stabilizers, and preservatives. Intravenous vehicles may include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose. In general, water, saline, aqueous dextrose, and related sugar solutions, as well as glycols such as propylene glycol or polyethylene glycol, are examples of liquid carriers, particularly for injectable solutions.
[0130] Injectable pharmaceutical carriers for injectable compositions are well known to those skilled in the art (see, e.g., Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Trissel, 15th ed., pages 622-630 (2009)).
[0131] Enteral administration The composition can be administered enterally. The carrier or diluent can be a solid carrier or diluent, such as a capsule or tablet for a solid formulation, a liquid carrier or diluent for a liquid formulation, or a mixture thereof.
[0132] For liquid preparations, pharmaceutically acceptable carriers can be, for example, aqueous or non-aqueous solutions, suspensions, emulsions, or oils.Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, and injectable organic esters, such as ethyl oleate.Aqueous carriers include, for example, water, alcoholic / aqueous solutions, cyclodextrins, emulsions, or suspensions, including saline and buffered media.
[0133] Examples of oils are oils of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, cod liver oil, sesame oil, cottonseed oil, corn oil, olive, petrolatum, and mineral.The fatty acids suitable for use in parenteral formulations include, for example, oleic acid, stearic acid, and isostearic acid.Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
[0134] Vehicles include, for example, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, and fixed oils. Formulations include aqueous and non-aqueous isotonic sterile injection solutions, which may contain, for example, antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions, which may contain suspending agents, solubilizers, thickeners, stabilizers, and preservatives. Vehicles may include, for example, fluid and nutrient replenishers, electrolyte replenishers, and replenishers based on Ringer's dextrose. In general, water, saline, aqueous dextrose, and related sugar solutions are examples of liquid carriers. These may also be formulated with proteins, fats, sugars, and other components of infant formulas.
[0135] In some embodiments, the composition is formulated for oral administration.Oral formulations can be in the form of chewing gum, gel strips, tablets, capsules or lozenges.The encapsulating material for preparing enteric-coated oral formulations includes cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate and methacrylic acid ester copolymer.In certain embodiments, solid oral formulations, such as capsules or tablets, are provided.Elixir and syrup are also well-known oral formulations.
[0136] How to use Compositions of dendrimers conjugated to one or more radionuclides or one or more MRI imaging agents are suitable for several applications, including but not limited to, diagnostic, therapeutic, and analytical applications. In particular, methods are disclosed for identifying and labeling one or more sites of inflammation or cancer in a subject by administering a dendrimer composition to the subject.
[0137] Macrophages (Mφ) play many important roles in the immune response of infected tissues through a polarized activation phase. Activated macrophages (Mφ*) are primarily classified as M1 (pro-inflammatory) and M2 (anti-inflammatory) macrophages. Both M1 and M2 macrophages play important roles in the inflammatory process of phagocytosis, antigen presentation, and scavenging activity (M1) and in the process of wound healing and tumor growth (M2). However, direct targeting of select populations of macrophages, i.e., distinguishing between non-activated and activated macrophages (Mφ*), remains a challenging task.
[0138] Compositions of dendrimers conjugated to one or more radionuclides or one or more MRI imaging agents are suitable for in vivo diagnosis and imaging of certain conditions or states in a subject, such as one or more inflammatory diseases such as rheumatoid arthritis, neuroinflammation such as cerebral palsy, neurodegenerative disorders such as Alzheimer's disease and ALS, and cancer in a subject in need thereof. In particular, the methods and compositions of the present disclosure are suitable for diagnosing, imaging, and / or treating one or more diseases or conditions associated with activated macrophages, including inflammatory diseases such as Alzheimer's disease, ALS, dementia, hepatitis, atherosclerosis, rheumatoid arthritis, and cancer.
[0139] Detection and imaging of areas of inflammation Methods for imaging inflammation using dendrimers conjugated to one or more radionuclides or one or more MRI imaging agents are described. The methods include administering an effective amount of the dendrimer conjugate to a subject with a disease or disorder associated with inflammation and / or cancer. In some embodiments, the dendrimer is conjugated to one or more radionuclides or one or more MRI imaging agents via an ether linkage for enhanced in vivo stability.
[0140] In some embodiments, the method is suitable for imaging one or more areas of inflammation associated with systemic viral and / or bacterial infection, systemic inflammatory response syndrome, sepsis, or septic shock. In some embodiments, the method is suitable for imaging one or more areas of inflammation caused by any mechanism of macrophage activation, including macrophage activation syndrome. In some embodiments, the method is suitable for imaging one or more areas of inflammation associated with multi-organ dysfunction, including neuroinflammation. In some embodiments, the method is suitable for imaging one or more areas of inflammation associated with hyperreactive M1 macrophages and / or elevated pro-inflammatory markers, such as IL-6, CRP, ferritin, and IL-1b. In some embodiments, the method is suitable for imaging one or more areas of inflammation characterized by a cytokine storm.
[0141] Autoimmune or inflammatory disorders Described herein are methods for using dendrimers conjugated to one or more radionuclides or one or more MRI imaging agents to image and / or diagnose inflammation associated with one or more autoimmune or inflammatory diseases or disorders. Exemplary autoimmune or inflammatory diseases or disorders include rheumatoid arthritis, systemic lupus erythematosus, alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behçet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue dermatitis, chronic fatigue syndrome-immune deficiency syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinin disease, CREST syndrome, Crohn's disease, and rheumatoid arthritis. Gore's disease, dermatomyositis, juvenile dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Graves' disease, Guillain-Barré, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, insulin-dependent diabetes mellitus (type 1), juvenile arthritis, Meniere's disease, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglanular syndrome syndromes), polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, Takayasu's arteritis, temporal arteritis / giant cell arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, and Wegener's granulomatosis.
[0142] In some embodiments, the inflammation is chronic inflammation, which is a long-term, dysregulated, maladaptive response involving active inflammation, tissue destruction, and attempts at tissue repair. Persistent inflammation is associated with many chronic human conditions and diseases, including allergies, atherosclerosis, cancer, arthritis, and autoimmune diseases.
[0143] Neuroinflammation Methods of using dendrimers conjugated to one or more radionuclides or one or more MRI imaging agents for imaging and / or diagnosing neuroinflammation are also described.
[0144] Neuroinflammation mediated by activated microglia and astrocytes is a key feature of various neurological disorders, making it a potential therapeutic target (Hagberg, H et al., Annals of Neurology 2012, 71, 444; Vargas, DL et al., Annals of Neurology 2005, 57, 67; and Pardo, CA et al., International Review of Psychiatry 2005, 17, 485). Multiple scientific reports suggest that reducing neuroinflammation early by targeting these cells can delay the onset of disease and, in turn, provide a longer therapeutic window for treatment (Dommergues, MA et al., Neuroscience 2003, 121, 619; Perry, VH et al., Nat Rev Neurol 2010, 6, 193; Kannan, S et al., Sci. Transl. Med. 2012, 4, 130ra46; and Block, ML et al., Nat Rev Neurosci 2007, 8, 57). Delivering active agents across the blood-brain barrier (BBB) is a challenging task. Neuroinflammation causes the breakdown of the blood-brain barrier (BBB). The impaired BBB in neuroinflammatory disorders can be exploited to transport drug-loaded nanoparticles throughout the brain (Stolp, HB et al., Cardiovascular Psychiatry and Neurology 2011, 2011, 10; and Ahishali, B et al., International Journal of Neuroscience 2005, 115, 151).
[0145] The compositions and methods can be used to deliver imaging / diagnostic agents to sites of neuroinflammation associated with neurological or neurodegenerative diseases or disorders, or central nervous system disorders. In some embodiments, the compositions and methods are effective for selectively delivering PET imaging probes to activated macrophages associated with neuroinflammation. For example, the compositions and methods can be used to treat diseases or disorders such as Parkinson's disease (PD) and PD-related disorders, Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and other dementias, prion diseases such as Creutzfeldt-Jakob disease, corticobasal degeneration, frontotemporal dementia, HIV-associated cognitive impairment, mild cognitive impairment, motor neuron disease (MND), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), Friedreich's ataxia, Lewy body disease, Alper's disease, Batten disease, cerebro-oculo-skeletal syndrome, corticobasal degeneration, Gerstmann-Straussler-Scheiker disease, kuru, Leigh's disease, monomelic muscular atrophy (MONA), and others. Subjects with dementia, dementia with Lewy bodies (DLB), lacunar syndrome, hydrocephalus, Wernicke-Korsakoff syndrome, post-encephalitic dementia, cognitive impairment and dementia associated with cancer and chemotherapy, and depression-induced dementia and pseudodementia can be imaged, diagnosed, and / or treated.
[0146] In some embodiments, the methods and compositions of the present disclosure can be used to image one or more neuroinflammatory sites in a subject, where the one or more neuroinflammatory sites are associated with a neurodegenerative disorder, such as Alzheimer's disease or ALS. In some embodiments, the methods and compositions of the present disclosure can be used to image and / or treat a neurodegenerative disorder, such as Alzheimer's disease or ALS. The inventors demonstrated that the labeled dendrimers of the present disclosure detected neuroinflammation in the cortex and hippocampus of mice with early Alzheimer's plaques, whereas a TSPO radiotracer failed to detect neuroinflammation in these mice (Example 7). The improved sensitivity and selectivity of the labeled dendrimers compared to the TSPO radiotracer in a neuroinflammation model demonstrates the effectiveness of the labeled dendrimers as imaging agents for detecting neuroinflammatory sites associated with neurodegenerative disorders.
[0147] In some embodiments, the disorder is a peroxisomal disorder or leukodystrophy characterized by adverse effects on the growth or maintenance of the myelin sheath that insulates nerve cells. Leukodystrophies include, for example, 18q syndrome with myelin basic protein deficiency, acute disseminated encephalomyelitis (ADEM), acute disseminated leukoencephalitis, acute hemorrhagic leukoencephalopathy, X-linked adrenoleukodystrophy (ALD), adrenomyeloneuropathy (AMN), Aicardi-Goutières syndrome, Alexander disease, adult-onset autosomal dominant leukodystrophy (ADLD), autosomal dominant diffuse leukoencephalopathy with neuroaxonal spheroids (HDLS), autosomal dominant delayed-onset leukoencephalopathy, ataxia of childhood with diffuse CNS hypomyelination (CACH or vanishing white matter disease), Canavan disease, autosomal dominant cerebral arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebrotendinous xanthomatosis (CTX), and craniometaphyseal dysplasia with leukoencephalopathy. Dysplasia), cystic leukoencephalopathy with RNASET2, widespread cerebral white matter abnormalities without clinical symptoms, familial adult-onset leukodystrophy manifesting as cerebellar ataxia and dementia, familial leukodystrophy with adult-onset dementia and abnormal glycolipid storage, globoid cell leukodystrophy (Krabbe disease), hereditary adult-onset leukodystrophy resembling chronic progressive multiple sclerosis, hypomyelination with atrophy of the basal ganglia and cerebellum (HABC), hypomyelination, hypogonadotropism, hypogonadism, and hypodontia (4H syndrome), lipomembranous dysplasia with leukodystrophy Osteodysplasia (Nasu disease), Metachromatic Leukodystrophy (MLD), Megalocephalic Leukodystrophy with Subcortical Cysts (MLC), Neuroaxonal Leukoencephalopathy with Axonal Spheroids (Hereditary Diffuse Leukoencephalopathy with Spheroids - HDLS), Neonatal Adrenoleukodystrophy (NALD), Oculodentodigital Dysplasia with Cerebral White Matter Abnormalities (Oculodetatoldigital Dysplasia)Dysplasia), normochromatic leukodystrophy with pigmented glia, ovarian leukodystrophy syndrome, Pelizaeus-Merzbacher disease (X-linked spastic paraplegia), Refsum disease, Sjögren-Larsen syndrome, Sudanophilic leukodystrophy, van der Knaap syndrome (vacuolar leukodystrophy with subcortical cysts or MLCs), childhood ataxia with vanishing white matter disease (VWM) or diffuse hypomyelination of the central nervous system (CACH), X-linked adrenoleukodystrophy (X-ALD), and Zellweger spectrum disorders including Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease, leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL), or DARS2 leukoencephalopathy. In some embodiments, the leukodystrophy is adrenoleukodystrophy (ALD) (including X-linked ALD), metachromatic leukodystrophy (MLD), Krabbe disease (globoid cell leukodystrophy), or DARS2 leukoencephalopathy.
[0148] In some embodiments, the subject has an excitotoxicity disorder.Excitotoxicity is a process in which nerve cells are overstimulated and thus become damaged.Several conditions are associated with excitotoxicity, including stroke, traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, and spinal cord injury.Damage to nerve cells leads to corresponding neurological symptoms that may vary depending on which cells are damaged and how extensive the damage is.Thus, in some embodiments, the dendrimer / agent complex is used to image or diagnose one or more excitotoxic disorders.
[0149] In some embodiments, the compositions and methods can be used to deliver imaging / diagnostic agents to sites of neuroinflammation, particularly microglia-mediated neuroinflammation, hi some embodiments, the disorder is maladaptive neuroinflammation, for example, maladaptive inflammation following traumatic brain injury.
[0150] In vivo cancer detection, imaging, and / or treatment Also provided are methods of imaging, diagnosing, and / or treating cancer and / or metastatic cancer, comprising administering an effective amount of the composition to a subject in need thereof. Also disclosed are any of the disclosed dendrimer compositions for use in localizing cancer and / or metastatic cancer in a subject.
[0151] The compositions and methods are useful for imaging, diagnosing, and / or treating subjects with benign or malignant tumors by slowing or inhibiting tumor growth in a subject, reducing tumor growth or size, inhibiting or reducing tumor metastasis, and / or inhibiting or reducing symptoms associated with tumor development or growth.
[0152] In some embodiments, dendrimers conjugated via ether linkages to one or more radionuclides or one or more MIR imaging agents are used for cancer imaging by positron emission tomography (PET). Exemplary PET imaging agents for cancer imaging include: 18 F (fluorine-18), 89 Zr (zirconium-89), 90 Y (yttrium-90), and 177 Lu (ruthenium-177). Exemplary MRI imaging agents for cancer imaging include Gd, Mn, BaSO4, iron oxide, and iron platinum.
[0153] Malignant tumors that can be diagnosed and / or treated are classified according to the embryonic origin of the tissue from which the tumor originates. Carcinomas are tumors that arise from endodermal or ectodermal tissues, such as the skin or the epithelial lining and glands of internal organs. The compositions are particularly useful for imaging, diagnosing, and / or treating carcinomas. Less common sarcomas originate from mesodermal connective tissues, such as bone, fat, and cartilage. Leukemia and lymphoma are malignant tumors of hematopoietic cells in the bone marrow. Leukemias grow as single cells, while lymphomas tend to grow as tumor masses. Malignant tumors can appear in multiple organs or tissues of the body, establishing cancer.
[0154] Cancer types that can be diagnosed, imaged, and / or treated by the provided compositions and methods include, but are not limited to, cancers such as vascular cancers, e.g., multiple myeloma, bone, bladder, brain, breast, cervical, colorectal, esophageal, renal, liver, lung, nasopharyngeal, pancreatic, prostate, skin, stomach, and uterine adenocarcinomas and sarcomas. In some embodiments, the compositions are used to treat multiple cancer types simultaneously. The compositions can also be used to treat metastases or tumors in multiple locations.
[0155] Exemplary tumor cells include cancers, such as leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, including myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia, Leukemias and myelodysplastic syndromes, chronic leukemias, including but not limited to chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, including but not limited to Hodgkin's disease, non-Hodgkin's disease; multiple myelomas, including but not limited to smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma, and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, including but not limited to bone Sarcomas, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal osteosarcoma, soft tissue sarcoma, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, schwannoma, rhabdomyosarcoma, synovial sarcoma; brain tumors, including but not limited to glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, non-glial tumors, acoustic neuroma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary cerebral lymphoma; breast cancers, including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast carcinoma breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal gland cancer, including but not limited to pheochromocytoma and adrenocortical carcinoma; thyroid cancer, including but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; pancreatic cancer, including but not limited to insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumors, and carcinoid or islet cell tumors; pituitary gland cancer, including but not limited to Cushing's disease, prolactin-secreting tumors, acromegaly, and diabetes insipidus;Cancers of the eye, including but not limited to intraocular melanoma, such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; cancers of the vagina, including but not limited to squamous cell carcinoma, adenocarcinoma, and melanoma; cancers of the vulva, including but not limited to squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cancers of the cervical cervix, including but not limited to squamous cell carcinoma and adenocarcinoma; cancers of the uterine cervix, including but not limited to endometrial carcinoma and uterine sarcoma; cancers of the ovary, including but not limited to ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; cancers of the esophagus, including but not limited to squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; cancers of the stomach, including but not limited to adenocarcinoma rectal cancer; liver cancer, including but not limited to hepatocellular carcinoma and hepatoblastoma; gallbladder cancer, including but not limited to adenocarcinoma; cholangiocarcinoma, including but not limited to papillary, nodular, and diffuse; lung cancer, including but not limited to non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large cell carcinoma, and small cell lung carcinoma; testicular cancer, including but not limited to germinal tumor, seminoma, undifferentiated, classic (typical), spermatocytic, non-seminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk sac tumor), prostate cancer, including but not limited to adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancer oral cancers, including but not limited to squamous cell carcinoma; basal carcinoma; salivary gland cancers, including but not limited to adenocarcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma; pharyngeal cancers, including but not limited to squamous cell carcinoma and warts; skin cancers, including but not limited to basal cell carcinoma, squamous cell carcinoma, and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentigo melanoma;Kidney cancers, including but not limited to renal cell carcinoma, adenocarcinoma, Grawitz tumor, fibrosarcoma, transitional cell carcinoma (renal pelvis and / or ureter); Wilms tumor; bladder cancers, including but not limited to transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, and carcinosarcoma tumor cells;
[0156] In some embodiments, the subject being treated is a subject with one or more solid tumors. A solid tumor is an abnormal mass of tissue that typically contains no cystic or liquid areas. A solid tumor can be benign (not cancerous) or malignant (cancer). Examples of solid tumors are sarcoma, carcinoma, and lymphoma. In some embodiments, the compositions and methods are effective for treating one or more symptoms of cancer of the skin, lung, liver, pancreas, brain, kidney, breast, prostate, colon and rectum, bladder, etc. In further embodiments, the tumor is localized lymphoma or follicular lymphoma.
[0157] In some embodiments, the subject to be treated is a subject with any type of solid tumor or brain metastasis.Solid tumors are formed in cancerous tissues in organs of the body.Exemplary organs include, but are not limited to, the brain, breast, lung, pancreas, kidney, liver, prostate, ovary, lung, thyroid gland, and pituitary gland.Brain metastasis is a disease in which malignant (cancer) cells originating from another region of the body (for example, lung or breast) invade the brain and form a solid tumor mass.
[0158] Radiopharmaceutical Treatment Radiopharmaceutical therapy (RPT) has emerged as a safe and effective targeted approach for treating many types of cancer. Compositions and methods are useful for specifically delivering radiation to targeted cells in tumor regions. In some embodiments, dendrimers conjugated to one or more radionuclides via ether linkages are used for radiopharmaceutical therapy in treating cancer. Suitable radionuclides include both beta particle and alpha particle emitters. Exemplary radionuclides for radiopharmaceutical therapy include: 18 F (fluorine-18), 89Zr (zirconium-89), 90 Y (yttrium-90), 131 I (iodine-131), 153 Sm (samarium-153), 166 Ho, 177 Lu (ruthenium-177), rhenium-186, 211 At, 212 Pb, 223 Ra (radium-223), 225 Ac, and 227 Th is an example.
[0159] Tumor cells utilize immunosuppressive mechanisms to establish a strongly immunosuppressive tumor microenvironment (TME), which inhibits antitumor immune responses and supports disease progression. Many cell types, including cancer-associated fibroblasts, myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and tumor-associated macrophages (TAMs), are thought to contribute to the generation of the immunosuppressive TME. In some embodiments, the dendrimer / radionuclide is specifically delivered to one or more reactive immune cells in the tumor region. In some embodiments, the dendrimer / radionuclide is specifically delivered to cancer-associated fibroblasts, MDSCs, Tregs, and / or TAMs.
[0160] Thus, a method for depleting, inhibiting, or reducing one or more reactive immune cells at tumor sites is described. Exemplary reactive immune cells include tumor-tolerant and immunosuppressive immune cells, such as TAM and MDSC. A method for depleting, inhibiting, or reducing tumor-associated macrophages (TAM, or M2-like macrophages) and / or MDSC in tumor tissue of a subject is described by selectively delivering radiation therapy to one or more TAM and / or MDSC in tumor tissue. The method comprises administering to the subject a dendrimer complex comprising one or more radionuclides in an amount effective to deplete, inhibit, or reduce the amount of TAM and / or MDSC in tumor tissue. In some embodiments, the method delivers radiation therapy to the tumor site, and is effective to kill, deplete, or reduce target cells as well as surrounding tumor cells.
[0161] In some embodiments, the radionuclide-labeled dendrimer is further conjugated to one or more anti-tumor drugs, including STING agonists, CSF1R inhibitors, PARP inhibitors, VEGFR tyrosine kinase inhibitors, EGFR tyrosine kinase inhibitors, MEK inhibitors, glutaminase inhibitors, TIE II antagonists, and CXCR2 inhibitors.
[0162] Exemplary anti-tumor agents also include idarubicin, imatinib, irinotecan, exemestane, etoposide, epirubicin, oxaliplatin, octreotide, capecitabine, carboplatin, carmofur, cladribine, clarithromycin, gefitinib, gemcitabine, cyclophosphamide, cisplatin, cytarabine, zinostatin, cetuximab, tamoxifen, daunorubicin, dacarbazine, dactinomycin, tegafur, topotecan, toremifene, doxifluridine, riboflavin ... Also included are cyclosporine, doxorubicin, docetaxel, nimustine, docetaxel, paclitaxel, vincristine, vindesine, vinblastine, nedaplatin, pirarubicin, fluorouracil, flutamide, bleomycin, fadrozole, mitomycin, fludarabine, prednisone, pentostatin, mitoxantrone, medroxyprogesterone, mercaptopurine, mitotane, zinostatin, rapamycin, cyclosporine, mycophenolate mofetil, and mizoribine.
[0163] Other exemplary anti-tumor agents include inhibitors that target one or more of EGFR, ERBB2, VEGFR, Kit, PDGFR, ABL, SRC, and mTOR. In some embodiments, the one or more anti-tumor agents are inhibitors such as crizotinib, ceritinib, alectinib, brigatinib, bosutinib, dasatinib, imatinib, nilotinib, vemurafenib, dabrafenib, ibrutinib, palbociclib, sorafenib, ribociclib, cabozantinib, gefitinib, erlotinib, lapatinib, vandetanib, afatinib, osimertinib, ruxolitinib, tofacitinib, trametinib, axitinib, lenvatinib, nintedanib, pazopanib, regorafenib, sunitinib, vandetanib, dacomitinib, and ponatinib. In some embodiments, the one or more anti-tumor drugs are tyrosine kinase inhibitors, such as HER2 inhibitors, EGFR tyrosine kinase inhibitors.Exemplary EGFR tyrosine kinase inhibitors include gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib.
[0164] Further exemplary anti-tumor agents include anti-angiogenic agents, such as antibodies against vascular endothelial growth factor (VEGF), e.g., bevacizumab (AVASTIN®) and rhuFAb V2 (ranibizumab, LUCENTIS®), and other anti-VEGF compounds, e.g., aflibercept (EYLEA®); MACUGEN® (pegaptanim sodium, anti-VEGF aptamer or EYE001) (Eyetech Pharmaceuticals; pigment epithelium-derived factor(s) (PEDF); COX-2 inhibitors, such as celecoxib (CELEBREX®) and rofecoxib (VIOXX®); interferon alpha; interleukin-12 (IL-12); thalidomide (THALOMID®) and its derivatives, such as lenalidomide (REVLIMID®); squalamine; endostatin; angiostatin; ribozyme inhibitors, such as ANGIOZYME® (Sirna Therapeutics); multifunctional antiangiogenic agents, such as NEOVASTAT® (AE-941) (Aeterna Laboratories, Quebec City, Canada); receptor tyrosine kinase (RTK) inhibitors such as sunitinib (SUTENT®); tyrosine kinase inhibitors such as sorafenib (Nexavar®) and erlotinib (Tarceva®); antibodies against epidermal growth factor receptors such as panitumumab (VECTIBIX®) and cetuximab (ERBITUX®), and other anti-angiogenic agents known in the art.
[0165] Control The effect of the dendrimer / agent composition, optionally including one or more additional active agents, can be compared to a control. Suitable controls are known in the art and include, for example, untreated subjects or placebo-treated subjects. A typical control is a comparison of the subject's condition or symptom before and after administration of the targeted agent. The condition or symptom can be a biochemical, molecular, physiological, or pathological readout. For example, the effect of the dendrimer / agent composition on a particular symptom, pharmacological, or physiological indicator can be compared to the condition of an untreated subject or a subject before treatment. In some embodiments, the symptom, pharmacological, or physiological indicator is measured in the subject before treatment and again one or more times after the start of treatment. In some embodiments, the control is a reference level or average value determined based on measuring the symptom, pharmacological, or physiological indicator in one or more subjects (e.g., healthy subjects) who do not have the disease or condition being treated. In some embodiments, the effect of the treatment is compared to conventional treatments known in the art. In some embodiments, the untreated control subject suffers from the same disease or condition as the treated subject.
[0166] Dosage and Effective Amount The dosage and dosage regimen will depend on the severity and location of the disorder or condition and / or the method of administration, and can be determined by one skilled in the art.
[0167] In some embodiments, the active agent targets healthy cells not within or associated with diseased / damaged tissue, or does not otherwise modulate the activity or quantity of healthy cells, or modulates them at a reduced level compared to cells associated with inflammation or cells in the tumor region, thus reducing by-products and other side effects associated with the composition.
[0168] Pharmaceutical compositions are described that include a therapeutically effective amount of a dendrimer composition and a pharmaceutically acceptable diluent, carrier, or excipient. In some embodiments, the pharmaceutical composition includes an effective amount of a hydroxyl-terminated PAMAM dendrimer conjugated to one or more radionuclides. Radiotherapy or imaging doses are determined from clinical trials of subjects with varying degrees of inflammation and / or tumor size to determine optimal dose ranges.
[0169] Also provided are dosage forms of pharmaceutical compositions comprising dendrimer compositions. "Dosage form" refers to the physical form of a dose of a therapeutic compound, such as a capsule or vial, intended to be administered to a patient. The term "dosage unit" refers to the amount of a therapeutic compound administered to a patient in a single dose.
[0170] The actual effective amount of the dendrimer conjugate may vary depending on factors including the specific active agent administered, the specific composition formulated, the mode of administration, and the age, weight, condition, and route of administration and disease or disorder of the subject being treated. In some embodiments, the subject is a human. Generally, dosages may be lower for intravenous injection or infusion.
[0171] Generally, the timing and frequency of administration will be adjusted to balance the effectiveness of a given treatment or diagnostic schedule with the side effects of a given delivery system. Exemplary dosing frequencies include continuous infusion, single and multiple doses, e.g., hourly, daily, weekly, monthly, or yearly dosing.
[0172] In some embodiments, a dosage of the dendrimer composition is administered to a human once, twice, or three times daily or every other day, every second, third, fourth, fifth, or sixth day. In some embodiments, a dosage is administered about once or twice every week, every two weeks, every three weeks, or every four weeks. In some embodiments, a dosage is administered about once or twice every month, every two months, every three months, every four months, every five months, or every six months.
[0173] It will be understood by those skilled in the art that the dosing regimen can be any length of time that is sufficient to treat the disorder in the subject.In some embodiments, the regimen comprises a drug-free day (for example, drug-free) after one or more treatment cycles.The drug-free day can be 1, 2, 3, 4, 5, 6 or 7 days; or 1, 2, 3, 4 weeks, or 1, 2, 3, 4, 5 or 6 months.
[0174] kit The composition can be packaged in a kit.The kit can include a single dose or multiple doses of the composition that comprises one or more radionuclides that are encapsulated in, associated with, or conjugated with dendrimer, and instructions for administering the composition.Specifically, the instructions indicate that an effective amount of the composition is administered to the individual with the specific condition / disease indicated.The composition can be formulated as described above with reference to specific treatment method, and can be packaged in any convenient manner.
[0175] The compositions can be packaged in single vials or multi-vial kits containing all of the components necessary to prepare the conjugate. In some embodiments, multi-vial kits contain the same general components, but use more than one vial in reconstituting the radiopharmaceutical. Advantageously, the contents of the vials are lyophilized.
[0176] The kit may also contain stabilizers, bulking agents, such as mannitol, and other additives known to those skilled in the art, designed to aid in the lyophilization process.
[0177] The present invention will be further understood with reference to the following non-limiting examples. [Example]
[0178] Example 1 via two synthetic routes 18 Synthesis and characterization of F-labeled dendrimers 18The F dendrimer (i.e., compound 5 shown in Figure 1) is synthesized by using one of two chemical routes. For both routes, the first synthetic step is the synthesis of alkyne-terminated dendrimer 2, which has 10–12 acetylene groups on the surface of the dendrimer. As shown in Figure 1, a fourth-generation PAMAM dendrimer is used as an exemplary dendrimer to illustrate the synthetic route. Briefly, compound 2 is synthesized by partially modifying a hydroxyl PAMAM dendrimer (compound 1) by reacting it with propargyl bromide in the presence of a 2% sodium hydroxide solution in DMSO. The solution was stirred overnight at room temperature. Upon completion of the reaction, the pH was adjusted to approximately 7 with saturated ammonium chloride, and tangential flow filtration (TFF) was performed to purify the product.
[0179] Acetylene dendrimer (compound 2) 1 The compound was characterized using H NMR, where the internal amide peak between δ 8.05 and 7.70 ppm is the reference peak. A sharp peak corresponding to O-CH2-acetylene was present at δ 4.13 ppm, and proton integration indicated the addition of propargyl groups to the 10-12 arm dendrimer. HPLC chromatograms showed a shift in retention time from the starting G4-OH dendrimer, with the peak for dendrimer (compound 2) observed at 12.6 min. In the next step, 3-azidopropyl 4-methylbenzenesulfonate (compound 3) was clicked onto compound 2 using copper-catalyzed click chemistry to give compound 4. The click reaction was carried out in the presence of anhydrous DMF using CuBr and N,N,N',N'',N''-pentamethyldiethylenetriamine, followed by stirring for 2 hours. Compound 4 was quickly purified using TFF in water. An EDTA wash was also performed to remove free copper salts. Again, completion of the reaction was confirmed. 1 Monitored via 1 H NMR and HPLC. 1H NMR revealed the attachment of 8–10 molecules of compound (3). A multiplet corresponding to the aromatic CH from compound (3) was observed at δ 7.49 ppm, and a peak corresponding to the O-CH triazole formed after the click reaction was observed at 4.37 ppm. The internal amide protons of the dendrimer, the triazole protons, and the Ar protons from the tosyl group appeared between δ 8.05 and 7.70. The HPLC chromatogram of compound (4) showed a right shift toward the hydrophobic region compared to compound (3), appearing at 19.1 min (data not shown). Next, cold fluorine exchange of the tosyl group was carried out at 100 °C using potassium fluoride, cryptand 222, and anhydrous potassium carbonate in DMSO. The reaction was carried out for 30 min, and the product was recovered through rapid purification. 1 In H NMR, the proton corresponding to the tosyl group at δ 7.49 ppm completely disappeared, and the O-CH2 next to the tosyl group also shifted downfield at δ 4.40 ppm, as expected after fluorine exchange. The retention time of the cold fluorinated dendrimer (5) again shifted toward the hydrophilic region at 12 min in HPLC.
[0180] Using other synthetic routes, compound 3 was first obtained. 18 Labeling with F gave fluoro(18)-propyl azide (3a), which was then clicked with dendrimer 2 to give the final dendrimer compound 5. All intermediates and the final radiolabeled dendrimers were fully characterized.
[0181] Example 2 Plasma stability study of cold fluorinated dendrimers The stability of fluorinated dendrimers in plasma at physiological temperatures was evaluated. The fluorinated dendrimers were dissolved in mouse plasma at a concentration of 1 mg / ml, and the plasma solution was incubated at 37°C. At various time points, 0 h (control), 2 h, 5 h, and 8 h, plasma samples (1 ml) of the fluorinated dendrimers were separated by centrifugation using an Amicon molecular weight cutoff filter (3 kDa). The supernatants were collected and analyzed for their fluorine content by ion chromatography (IC). NHF was used as a standard. The percentage of fluorine in the supernatant at each time point was calculated based on the F in the supernatant, and the total amount of fluorine in the fluorinated dendrimers was calculated.
[0182] No defluorination (change in fluorine in the supernatant) was observed from the fluorinated dendrimer after 8 h of incubation at 37 °C in mouse plasma (Figure 2), indicating a highly stable fluorinated dendrimer conjugate.
[0183] Example 3 89 Synthesis and characterization of Zr-labeled dendrimers D-Deferoxamine 89 For the synthesis of Zr-labeled dendrimer 5 (Figure 3), synthesis began with the fourth-generation hydroxyl-terminated PAMAM dendrimer, PAMAM-G4-OH (1), and etherification was carried out at room temperature using allyl bromide, anhydrous cesium carbonate, and tetrabutylammonium iodide in DMF. The reaction was stirred overnight at room temperature. Upon completion, the reaction mixture was purified by performing TFF followed by lyophilization. 1 H NMR confirmed the formation of compound 2, with 9–10 allyl arms attached to the dendrimer. 1H NMR showed multiplets of -CH at δ 5.85-5.73 ppm, corresponding to the allyl group, and CH at δ 5.15 ppm. The purity of compound (2) was assessed using HPLC; a peak appeared at 7.9 min and was >98% pure. During the next step, cysteamine was added around the allyl group in an anti-Markovnikov manner using photochemical thiol-ene click. The reaction was carried out in anhydrous DMF, and 2,2-dimethoxy-2-phenylacetophenone was used as the photoinitiator for the reaction. The reaction was carried out under UV light at 365 nm for 8 hours. Upon completion, the DMF was evaporated, and TFF was performed to purify compound D-amine (3). Again, the reaction was 1 H NMR and HPLC were used to monitor. 1 Complete disappearance of the allyl peak in 1 H NMR confirmed successful completion of the reaction. 1 H NMR showed a -CH peak at δ 1.6 ppm, created after thiol insertion. After the amine-terminated dendrimer (3) was prepared, it was coupled with p-SCN-Bn-deferoxamine (DFO) in DMSO. The coupling was carried out overnight with stirring at pH 7.5. Product formation was again confirmed by 1 The conjugation was confirmed by H NMR, and the deferoxamine peak appeared in the NMR after conjugation. The N-acetyl peak of DFO appeared at δ 1.97, and the -CH2 peak from DFO appeared at δ 1.65-1.15 ppm. The final loading of DFO was calculated using proton integration, and it was found that 9-10 molecules were attached to the dendrimer (compound 4). Upon attachment of the DFO molecules, the HPLC peak corresponding to dendrimer-DFO (4) shifted to the hydrophobic side at 13.1 min. The final step was hot cleavage using zirconium oxalate. 89 The first step is to radiolabel the compound with Zr, where the hot Zr molecule is chelated with the DFO arm to give compound 5. The chelation reaction is carried out in HEPES buffer, pH 7.4. 89Zr(oxalate)2 is first neutralized with Na2CO3 and then incubated with DFO-dendrimer (compound 4). The radiolabeling reaction is carried out at room temperature on a stirring heat block for 60 minutes. After radiolabeling is achieved, the reaction is quenched with a 50 mM solution of DTPA. The radiolabeled dendrimer (compound 5) is purified by HPLC or a PD-10 column. The stability of the final construct is evaluated under physiological conditions in mouse and human plasma.
[0184] Example 4 Chelation of zirconium to dendrimer-DFO Chelation of zirconium in dendrimer-DFO conjugates was performed, and the success of the chelation was evaluated using HPLC, NMR, and ICP. Successful Zr chelation was confirmed by all three techniques. HPLC results showed that the polarity of the Zr-DFO-dendrimer was increased compared to D4-DFO, and the peaks became broader after chelation.
[0185] The dendrimer-DFO-Zr complex was 1 Further analysis was performed by 1 H NMR, which clearly revealed the interaction of the DFO protons with Zr by showing their absence due to their limited mobility as a result of chelation.
[0186] Zr chelation was also confirmed via inductively coupled plasma (ICP). Zirconium standard solutions were prepared by serial dilution of a commercially available Zr standard (998 ± 3 ppm) with 5% nitric acid (trace metals) solution. Standard solutions with concentrations of 0.1 ppm, 0.5 ppm, 1 ppm, 5 ppm, 10 ppm, 20 ppm, 50 ppm, and 100 ppm were prepared for calibration. Zr-DFO-dendrimer (1 mg) was dissolved in 10 ml of 5% nitric acid and used for ICP measurements. The DFO / dendrimer ratio was 10–11 / 1, while the Zr / dendrimer ratio was 13 / 1 by ICP measurement.
[0187] Example 5 In vitro plasma stability of Zr-labeled dendrimers The in vitro plasma stability of Zr-labeled dendrimers was evaluated at physiological temperatures. Zr-DFO-dendrimers were dissolved in human or mouse plasma at a concentration of 2 mg / ml and incubated at 37°C. At various time points, e.g., 0 h (control), 4 h, 24 h, 48 h, and 7 days, Zr-DFO-dendrimer plasma samples (1 ml) were separated by centrifugation using an Amicon molecular weight cutoff filter (3 kDa). Free Zr 4+ The supernatant containing Zr was collected and diluted (10-fold) with 5% nitric acid for ICP analysis. 4+ The concentration was calculated based on a standard calibration curve by the ICP instrument software. 4+ The percentage of released Zr in the supernatant was calculated by 4+ and calculated based on the total amount of Zr in the dendrimer-DFO-Zr conjugate. Less than 2% Zr release was observed after 72 h of incubation in plasma, suggesting the highly stable nature of the dendrimer-DFO-Zr conjugate (Figure 4).
[0188] The propargyl arms were introduced into the dendrimers using very mild conditions (2% sodium hydroxide), and the entire procedure is highly reproducible and facile. The developed synthetic process is highly adaptable for large-scale synthesis.
[0189] Example 6 Conjugated to antitumor drugs 90 Synthesis of Y-labeled dendrimers 90 Synthesis of Y-labeled hydroxyl dendrimers 90 For the construction of yttrium-labeled hydroxyl dendrimers, synthesis began with dendrimer-acetylene (compound 1), which was clicked with azide-PEG-amine using copper-catalyzed click in the presence of copper sulfate and sodium ascorbate (Figure 5). The dendrimer (compound 2) was purified using tangential flow filtration and lyophilized. HPLC and1 Characterization was performed with the aid of H NMR. Once the amine-functionalized dendrimer (compound 2) was prepared, it was further reacted with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-N-hydroxysuccinimide ester (DOTA-NHS) in DMSO at pH 7.5 to obtain dendrimer-DOTA (compound 3), in which 8–10 DOTA arms were attached to the dendrimer. In the final step, dendrimer-DOTA was reacted with hot yttrium in ammonium acetate buffer at pH 6.5–7.5. 90 It was converted into a Y-labeled dendrimer (compound 4). 90 The Y-labeled dendrimers were purified using a PD-10 column or radio-HPLC.
[0190] Synthesis of 90Y-labeled dendrimer-antitumor drug combinations Several preclinical studies have revealed that combining immunotherapy and / or chemotherapy with radiotherapy may be a promising strategy for synergistically enhancing treatment efficacy. Due to their multivalency, dendrimers serve as potential tools that allow for the precise introduction of multiple components (drugs, radionuclides, imaging, and ligands) into a single dendrimer with high reproducibility and purity. Radiotherapy and antitumor drugs can be combined in the same dendrimer construct to have synergistic effects. Figure 6 outlines a synthetic scheme for conjugating both radionuclides and antitumor drugs to dendrimers: first, the drug is attached using five or six acetylene arms on the dendrimer (compound 1), and DOTA is attached using the remaining arms. In the final step, the hot radionuclide is complexed to form the DOTA-labeled dendrimer-drug conjugate.
[0191] Example 7 For imaging of maladaptive neuroinflammation in mouse models of lipopolysaccharide-induced sepsis and neurodegenerative disease 18 F-labeled dendrimers Myeloid cells, such as reactive macrophages and microglia, as well as other components of the innate immune response, play important roles in the development and progression of many neurodegenerative diseases. PET imaging provides a noninvasive method for visualizing and quantifying inflammation in the brain and periphery (Jain, P. et al., JNM. 2020, 62 (8)1107-1112). However, the current gold-standard PET tracer, TSPO, does not specifically image macrophage activity.
[0192] OP-801 is a synthetic PAMAM hydroxyl dendrimer that crosses the BBB in the presence of inflammation and is selectively taken up (>95%) by reactive microglia and macrophages. After systemic administration, these hydroxyl dendrimers (without the need for any ligands or antibodies) cross the blood-brain barrier in the presence of neuroinflammation, selectively targeting reactive microglia / macrophages and astrocytes, with minimal uptake in healthy brain and tissue. Fluorescently labeled dendrimers have been successfully measured in reactive microglia in animals with neuroinflammation. These hydroxyl dendrimers are selectively endocytosed by reactive microglia in test animals, as demonstrated by >95% of reactive microglia containing the dendrimer within 4 hours after administration of a systemic dose. As shown in Figure 7A, the degree of hydroxyl dendrimer uptake in reactive microglia correlates with the degree of neuroinflammation and has been quantitatively assessed in acute neuroinflammation models of varying severity. These non-clinical studies involve testing a mouse model of ALS that has a superoxide dismutase 1 gene mutation (ALS(SOD1 mice)).
[0193] This study aimed to develop the first hydroxyl dendrimer-based PET tracer that targets reactive microglia and evaluate its potential to detect minor inflammation in a mouse model of lipopolysaccharide (LPS)-induced sepsis.
[0194] method In the 5xFAD transgenic mouse model, 7-month-old mice were intravenously administered G4 hydroxyl dendrimer conjugated with Cy5 label. Mice were sacrificed 48 hours after dosing and perfused with saline. Brain histology demonstrated selective uptake of the hydroxyl dendrimer by reactive microglia surrounding beta-amyloid plaques, but no detectable uptake by oligodendrocytes or neurons, and no detectable uptake by normal microglia, as demonstrated in Figure 7B. The degree of selectivity for reactive microglia compared with normal microglia suggests that OP-801 is more selective for areas of neuroinflammation than current imaging approaches based on the expression of proteins such as translocator protein (TSPO), which are present in both normal and reactive microglia and astrocytes.
[0195] To translate histological findings into in vivo molecular imaging approaches, hydroxyl dendrimers were radiolabeled via a two-step azide fluorination and Cu-catalyzed click reaction as shown in Figure 1. 18 F-labeled hydroxyl dendrimer (compound 10 in Figure 1 , 18 The product was formulated for injection using SEC, yielding 150-250 μCi (5-10 ng) per mouse. 18 F-OP-801) was injected 24 hours after intraperitoneal administration of 10 mg / kg LPS (n=6) or saline (n=5). Plasma stability was assessed at 60 min (n=4) and 150 min (n=4) post-injection. Dynamic PET images were acquired for 60 min, and static images were obtained by binning counts from 25-35 min or 50-60 min. Two LPS mice with very low mouse sepsis scores were excluded from the analysis (Shrum, B. et al., BMC Res Notes. 2014, 7 (233)). After imaging, mice were perfused, and organs were dissected; radioactivity was measured using a gamma counter. Tracer distribution in the brain was assessed using autoradiography and Nissl staining of sagittal brain sections. Adult female mice were used for all studies.
[0196] result As shown in Figures 7C and 7D, normal (saline) mice 18 F-OP-801 was rapidly excreted from the kidney to the bladder, consistent with results from another D4 hydroxyl dendrimer administered to healthy human volunteers (data not shown). In contrast, LPS-treated mice showed significant excretion throughout the peritoneal cavity and in the brain. 18 There was a significant uptake of F-OP-801, which correlated with the degree of inflammation. 18 This leads to activation of macrophages and microglia, which are targets of F-OP-801 and hydroxyl dendrimers.
[0197] A total of 50–60 minutes of static PET imaging was performed to evaluate the composite MSS score (R 2 =0.94) 18 Dynamic imaging time-activity curves revealed a linear increase in F-OP-801 uptake. The optimal static imaging time was 18 The results showed that F-OP-801 uptake was significantly different between 25 and 60 minutes after injection (Figure 7E). Brain atlas analysis of PET images taken over a total of 50 to 60 minutes showed that uptake was significantly (p<0.05) different between LPS- and saline-treated mice in the cortex, medulla, olfactory bulb, and pons (Figure 7F). Hippocampal uptake, as demonstrated by static images taken between 25 and 35 minutes, was significantly different (p=0.045) between LPS- and saline-treated mice (Figures 7G and 7H). Ex vivo biodistribution data and PET showed similar uptake patterns in LPS (n=4) versus saline (n=5) mice (Figure 7I), as described in more detail below.
[0198] To determine potential dose-limiting organs (i.e., radiation dosimetry), 18 Imaging-based assessment of F-OP-801 biodistribution and ex vivo gamma counting was performed. 18F-OP-801 (150–250 μCi) was administered intravenously to healthy female C57BL / 6 mice (n = 30). Four mice were euthanized without perfusion at each time point: 5, 15, 30, 60, 90, and 270 min. Organs were dissected, weighed, and measured for radioactivity in a gamma counter. For image-based dosimetry studies, 60-min dynamic PET / CT imaging was performed in healthy male (n = 5) and healthy female (n = 3) C57BL / 6 mice, followed by 5-min static scans at 90 and 270 min. Regions of interest (ROIs) were manually drawn over the organs in each image to quantify radioactivity within each structure. These data (image-based quantification of organs in male mice and image + gamma counter quantification of female mice) were converted to estimated human %ID / g and entered into OLINDA. Based on preliminary PET imaging of healthy control female mice, the dose-limiting organs are expected to be the kidneys and bladder (Figure 7I). These results were supported by gamma counting biodistribution studies. Significant differences were observed in organs expected to have an increased immune response, including the liver (2.7 ± 2.20 saline vs. 35.2 ± 35.14 LPS %ID / g, p = 0.032), lung (2.9 ± 4.34 vs. 36.4 ± 27.27 %ID / g, p = 0.032), and spleen (2.0 ± 1.60 vs. 26.2 ± 20.98 %ID / g, p = 0.016).
[0199] Autoradiography results confirmed the brain uptake from the PET images (Figure 7J). A plot of LPS MSS score vs. %ID / g in the whole brain from the 50-60 min PET is shown in Figure 7K, along with the linear regression and 95% confidence intervals. These results 18 Using hydroxyl dendrimers such as F-OP-801, we demonstrate the ability to selectively image systemic inflammation as well as neuroinflammation.
[0200] Plasma stability and dosimetry were also performed in mice. 18Ex vivo plasma stability of F-OP-801 was assessed at 60 and 150 minutes after injection (n = 4 / group). Plasma stability averaged >95% after 150 minutes in female mice (Figure 7L).
[0201] In summary, this study demonstrates that labeled hydroxyl dendrimers are highly specific PET tracers with excellent potential for noninvasive molecular imaging of maladaptive inflammation, including imaging of ALS and Alzheimer's patients.
[0202] 18 To further evaluate the ability of F-OP-801 to image neuroinflammation in neurodegenerative diseases, we used the 5xFAD transgenic mouse model. 5xFAD transgenic mice (B6SJL-Tg(APPSwFlLon,PSEN1*M146L *L286V)6799Vas) express human APP and PSEN1 transgenes and develop amyloid plaques within the first few months of life. Previous studies with TSPO PET radiotracers have shown that F-OP-801 does not significantly affect neuroinflammation in neurodegenerative diseases. 18 Neuroinflammation could only be detected by F-GE180 at approximately 6 months of age (approximately 26 weeks of age). 5xFAD female mice and age-matched controls were treated with the TPSO radiotracer at 3.75 months of age. 18 Compared to F-GE180 18 F-OP-801 was evaluated. 18 F-OP-801 (150–250 μCi) was injected as an IV bolus into 3.75-month-old wild-type (n=7) and 5xFAD female mice (n=12). 18 F-GE180 (150–250 μCi) was administered to 3.75-month-old 5xFAD transgenic (n=5) and wild-type (n=4) female mice. Ten-minute static PET / CT images were acquired 50–60 min post-injection. A VivoQuant brain atlas was overlaid on the CT images and registered to the PET to quantify uptake in specific brain regions. 18F-OP-801 produced a 3-fold higher PET signal in 5xFAD mice compared to wild-type mice, 18 F-GE180 provided the smallest PET signal difference between 5xFAD mice and wild-type controls (Figures 7M and 7N; Table 1). Table 1: At 3.75 months of age 18 F-OP-801 or 18 Comparison of transgenic (TG) to wild-type (WT) ratios (equivalent to signal-to-background ratios) in brain regions known to exhibit amyloid pathology in 5xFAD mice treated with either F-GE180 or F-GE180. [Table 1]
[0203] 18 When F-OP-801 was administered to 5-month-old mice, a 4-fold higher PET signal was observed in 5xFAD mice compared to wild-type controls (Figure 7O; Table 2). At 5 months, there was a significant difference between 5xFAD transgenic (TG) and wild-type (WT) mice in the cortex (p=0.005) (TG: 0.26 ± 0.095 SUV, WT: 0.11 ± 0.041 SUV), hippocampus (p=0.017) (TG: 0.18 ± 0.065 SUV, WT: 0.10 ± 0.026 SUV), and whole brain (p=0.004) (TG: 0.20 ± 0.082 SUV, WT: 0.10 ± 0.039 SUV). 18 Significant differences in F-OP-801 uptake were observed. 18 We demonstrate that F-OP-801 can detect early neuroinflammation with high sensitivity due to its superior selectivity compared to the lower selectivity of TSPO PET radiotracers, and provides information on the progression of neuroinflammation over time. Table 2: At 5 months of age 18 Transgenic (TG) to wild-type (WT) ratios (equivalent to signal-to-background ratios) in brain regions known to exhibit amyloid pathology in 5xFAD mice treated with F-OP-801 [Table 2]
[0204] GLP toxicology studies in Sprague Dawley rats were conducted with OP-801 (cold) administered as a single dose (Day 1) at a safety factor of >1000 times the expected human mass dose to mimic the projected human dose exposure from imaging procedures (Table 3). GLP studies were conducted at Charles River Laboratories with 10 male and 10 female Sprague Dawley rats per group. Test groups included vehicle control, low, medium, and high doses of OP-801 (cold) administered on Day 1. Five rats per sex per group were euthanized on Days 2 and 13. Clinical pathology, gross necropsy, and histology for a full set of standard histological and gross lesions were performed on each test animal after sacrifice. Additional rats (6 per sex per group) were evaluated for toxicokinetics. Toxicokinetic analysis was performed by AIT Biosciences using a validated LC / MS method for detecting OP-801 in rat plasma. Table 3: OP-801 Single-Dose Rat GLP Toxicology Study Design (Study 3101-011) [Table 3] Endpoint - GLP Rat Study Mortality check (daily, morning and afternoon). Clinical observations (1 and 4 hours after dosing) and daily on non-dosing days. ·Weight (daily). Feed consumption (daily). · Ophthalmological examination (before treatment and before the end of 15 days). · Recording of necropsy and gross findings (days 2, 9, and 15). · Organ weight. ·Histopathology. A comprehensive list of tissues from all control and high-dose animals as well as gross lesions and target organs from lower dose groups. Toxicokinetics (post-dosing on days 1 and 8).
[0205] Example 8 Hydroxyl dendrimer-based SPECT imaging agents for targeted imaging of tumors in an orthotopic mouse glioblastoma multiforme model. 111 In-D6-B483 Hydroxyl dendrimers (HDs) are taken up by tumor-associated macrophages and microglia (TAMs) with superior selectivity to antibodies in animal models of orthotopic glioblastoma multiforme (GBM). 111 Initial attempts to develop In-D6-B483, a HD with covalently linked DOTA attached to surface hydroxyl groups, showed potential for targeting orthotopic GBM in mouse models but required further optimization for clinical use (Liaw et al, Bioeng Transl Med 2020; 5 (2): 1-12 (https: / / doi.org / 10.1002 / btm2.10160); Cleland et al, Cancer Res 2020; 80 (16 Suppl): Abstract 679; Cleland et al, Clin Cancer Res 2021; 27 (8 Suppl): Abstract PO-097).
[0206] Current approaches to imaging GBM rely on magnetic resonance imaging (MRI) to diagnose and grade the glioma status. 111 In-D6-B483 has the potential to quantify the degree of TAM involvement, which may correlate with the severity of glioma. 111 Instead of In 90 HD may also be used for radiation therapy using Y. HD has been observed to be retained in the TAM for up to one month after a single dose, providing a local reservoir of radiation from systemic exposure (systemic clearance is within two days).
[0207] Methods: The synthesis of D6-B483 was achieved in two reaction steps. During the first synthetic step, partial propargylation of the dendrimer was achieved using sodium hydride and propargyl bromide. In the second step, azide-terminated DOTA was attached to the propargyl dendrimer to give D-B483. Figure 8 shows the 111 An example of the scheme and reaction conditions used for the synthesis of In-D6-B483 is shown below. For the synthesis of Cy5-labeled dendrimers, one or two propargyl functional groups on the dendrimer were reacted with Cy5 azide to obtain Cy5-D6-B483. Cy5-labeled D6-B483 (10 mg / kg) bearing either two or three or eight or ten DOTA moieties was administered intravenously to mice. Three mice per time point were sacrificed at 15 minutes, 4, 24, 48, and 96 hours post-dose. The amount of Cy5-D6-B483 was measured in the kidney and liver after tissue homogenization and extraction (Liao 2020). D6-B483 was heated to 85°C. 111 Mixing with InCl3 gave a labeling efficiency of 73%. The product was buffer exchanged to free HCl using a membrane centrifugation system (3 kDa cutoff). 111 The In was removed and formulated for injection in PBS. The final product had a radiochemical purity of 96%.
[0208] 111 The selective uptake of In-D6-B483 was evaluated in the brain and solid tumors. Twenty female mice were injected with 10 6 GL-261-luc2 cells were implanted by stereotactic intracranial (IC) surgery. Brain tumor size and location were measured by bioluminescence (BLI) and confirmed that tumors were 15-60 mm before administration. 3 Separate groups of 8 mice were randomly assigned to 6 GL-261-luc2 cells were implanted subcutaneously (SC) until the tumors reached 125–350 mm 3 (caliper measurement) and administered the drug. 111A single IV dose of In-D6-B483 (approximately 230 μCi, 45 μg) was given, and SPECT / CT images were obtained at 3-6, 24, 48, 72, and 96 hours post-dose. Example results are shown in Figure 9A. Gamma counting of tissues was performed within 24 hours after terminal sacrifice.
[0209] Results: HD has previously been demonstrated to be secreted by the kidney with minimal hepatic uptake in animals and humans (Lesniak et al, Mol. Pharmaceutics 1013;10:4560-4571). D6-B483 with 2-3 DOTAs had lower liver exposure than D6-B483 with 8-10 DOTAs, but similar kidney exposure. HD was measured in mouse serum for up to 4 days. 111 The stability of In-D6-B483 was 90% greater than that of the parental control. Using bioluminescence imaging, 12 IC tumor-bearing and 4 SC tumor-bearing mice were enrolled in the study. SPECT / CT imaging demonstrated approximately 1% ID / g in IC and SC tumors compared to approximately 1% ID / g in the contralateral brain. 111 showed relatively high uptake of In-D6-B483 (approximately 15% ID / g and 8% ID / g, respectively, as shown in Figure 9B).
[0210] Conclusion: 111 In-D6-B483 is a targeted, highly selective SPECT tracer for noninvasive imaging of brain tumors, allowing accurate quantification of HD uptake and corresponding TAM involvement. 111 In-D6-B483 is currently in development for Phase I trials in patients with GBM and brain metastases.
[0211] in large tumors (Fig. 10) and small tumors (Fig. 11) 111 The localization of In-D6-B483 was also evaluated. Large tumors were imaged by cryofluorescence tomography (CFT), which showed the localization of Cy5-D6-B483 after 48 hours (tumor size: 47 mm) (Figure 10, left panel). 111When large tumors (tumor size: 61 mm) were imaged using In-D6-B483 after 48 hours, a tumor / contralateral ratio of 8:1 was found (Figure 10, right panel). Small tumors were also imaged using cryofluorescence tomography (CFT), and localization of Cy5-D6-B483 was observed at 48 hours (tumor size: 6 mm) (Figure 11, left panel). 111 In-D6-B483 was also used to image tumors after 48 hours (tumor size: 9 mm) and demonstrated high sensitivity in detecting small tumors (Figure 11, right panel).
[0212] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims.
Claims
1. A composition comprising a hydroxyl-terminated dendrimer conjugated through an ether linkage, optionally via one or more linking moieties, to one or more radionuclides or one or more magnetic resonance imaging (MRI) contrast agents.
2. the dendrimer is a polyamidoamine (PAMAM) dendrimer, a polypropylamine (POPAM) dendrimer, a polyethyleneimine dendrimer, a polylysine dendrimer, a polyester dendrimer, an iptycene dendrimer, an aliphatic poly(ether) dendrimer, or an aromatic polyether dendrimer; Optionally, the dendrimer is a 4th, 5th, 6th, 7th, or 8th generation PAMAM dendrimer. The composition of claim 1.
3. The one or more radionuclides are 18 F. 51 Mn, 52 Fe, 60 Cu, 72As, 94m Tc, 110In, 124I, 125 I, 131 I, 123 I, 77 B, 76 B, 99m Tc, 51 Cr, 67 G.A. 68 G.A. 47 Sc, 167Tm, 141 C, 111 In, 168 Yb, 175 Yb, 140 La, 90 Y. 88 Y. 153 Sm, 166 Ho, 165 Dy, 166 Dy, 62 Cu, 64 Cu, 67 Cu, 97 Ru, 103 Ru, 186 Re, 188 Re, 203 Pb, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 149 P.M., 161 Tb, 177 Lu, 225 A c, 198 Au, and 199 Au, or 89 Zr; Optionally, the one or more radionuclides are 18 F, 89 Zr, 90 Y, 64 Cu, or 177 Lu; The composition according to any one of claims 1 to 2.
4. The one or more MRI contrast agents are Gd, Mn, BaSO 4 , iron oxide, and iron platinum; Optionally, the MRI contrast agent is Gd. The composition according to any one of claims 1 to 3.
5. A composition according to any one of claims 1 to 4 in an amount effective to selectively accumulate within reactive microglia and / or macrophages at sites of inflammation or in reactive immune cells in tumors.
6. The composition of any one of claims 1 to 5, further comprising one or more additional active agents.
7. A composition comprising a compound comprising a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, wherein the dendrimer comprises a high density of surface hydroxyl groups.
8. 8. The composition of claim 7, wherein the radionuclide or the MRI contrast agent is conjugated to the ester, ether, or amide linkage through a spacer.
9. the spacer comprises an alkyl group, a heteroalkyl group, or an alkylaryl group, and optionally the spacer comprises a peptide; and / or the spacer comprises polyethylene glycol; The composition of claim 8.
10. conjugation of said radionuclide or said MRI contrast agent occurs on less than 50% of the total surface functional groups of said dendrimer available prior to said conjugation; Optionally, conjugation of the radionuclide or the MRI contrast agent occurs on less than 5%, less than 10%, less than 20%, less than 30%, or less than 40% of the total surface functional groups of the dendrimer available prior to said conjugation. The composition according to any one of claims 7 to 9.
11. The radionuclide is 18 F. 51 Mn, 52 Fe, 60 Cu, 72As, 94m Tc, 110 In, 124I, 125 I, 131 I, 123 I, 77 B, 76 B, 99m Tc, 51 Cr, 67 G.A. 68 G.A. 47 Sc, 167Tm, 141 C, 111 In, 168 Yb, 175 Yb, 140 La, 90 Y. 88 Y. 153 Sm, 166 Ho, 165 Dy, 166 Dy, 62 Cu, 64 Cu, 67 Cu, 97 Ru, 103 Ru, 186 Re, 188 Re, 203 Pb, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 149 P.M., 161 Tb, 177 Lu, 225 A c, 198 Au, 199 Au, and 89 Zr; Optionally, the radionuclide is 18 F, 89 Zr, 90 Y, 64 Cu, or 177 Lu; The composition according to any one of claims 7 to 10.
12. The MRI contrast agent is Gd, Mn, BaSO 4 , iron oxide, and iron platinum; Optionally, the MRI contrast agent is Gd. The composition according to any one of claims 7 to 11.
13. 13. The composition of any one of claims 7 to 12, wherein the dendrimer is selected from the group consisting of polyamidoamine (PAMAM) dendrimers, polypropylamine (POPAM) dendrimers, polyethyleneimine dendrimers, polylysine dendrimers, polyester dendrimers, iptycene dendrimers, aliphatic poly(ether) dendrimers, and aromatic polyether dendrimers.
14. the zeta potential of the compound is between −25 mV and 25 mV; Optionally, the zeta potential of the compound is between −20 mV and 20 mV, between −10 mV and 10 mV, between −10 mV and 5 mV, between −5 mV and 5 mV, or between −2 mV and 2 mV; The composition according to any one of claims 7 to 13.
15. The composition according to any one of claims 7 to 14, wherein the compound has a neutral or near neutral surface charge.
16. the dendrimer is conjugated to the radionuclide or the MRI contrast agent through an ether or amide linkage; Optionally, the dendrimer is conjugated to the radionuclide or the MRI contrast agent through an ether linkage. The composition according to any one of claims 7 to 15.
17. 17. A pharmaceutical composition comprising the composition of any one of claims 1 to 16 and a pharma- ceutical acceptable excipient, optionally wherein the composition is formulated for intraperitoneal, intravenous, intrathecal, intratumoral or oral administration.
18. 1. A composition for use in a method for detecting or imaging one or more inflammatory and / or cancer cells in a subject in need thereof, comprising a compound comprising a dendrimer conjugated to a radionuclide or an MRI contrast agent via an ester, ether, or amide linkage, said dendrimer comprising a high density of surface hydroxyl groups, said method comprising administering said composition to said subject; Optionally, the composition is administered to the subject systemically or via an intraperitoneal, intravenous, intrathecal, intratumoral or oral route; and / or Optionally, the composition is administered in an amount effective to detect, diagnose, or monitor one or more sites of inflammation or cancer in the subject; and / or Optionally, said one or more sites of inflammation in said subject are characterized by: associated with one or more inflammatory diseases, or associated with sepsis or septic shock, or caused by any mechanism of macrophage activation, including macrophage activation syndrome, or One or more autoimmune diseases or disorders, Optionally, the one or more autoimmune diseases or disorders are selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, Sjogren's syndrome, myasthenia gravis, Graves' disease, Addison's disease, celiac disease, Hashimoto's thyroiditis, pernicious anemia, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, vasculitis, systemic lupus erythematosus (SLE), type I diabetes, inflammatory bowel disease, and thyroid disease. one or more neuroinflammatory sites in the central nervous system, optionally wherein said one or more neuroinflammatory sites in the central nervous system in said subject are associated with Alzheimer's disease; associated with amyotrophic lateral sclerosis (ALS), associated with one or more autoimmune diseases or disorders, and / or Optionally, the subject has cancer, and optionally, the cancer is any type of solid tumor or brain metastasis; and / or Optionally, the method further comprises imaging the subject with a molecular imaging device to detect the dendrimer conjugated to one or more radionuclides in the subject, wherein detection of the dendrimer conjugated to one or more radionuclides indicates the presence of inflammatory or cancerous cells, and optionally, the molecular imaging device comprises a gamma camera for positron emission tomography (PET) scanning or a scanner for magnetic resonance imaging. composition.
19. The composition according to any one of claims 1 to 18 for detecting or imaging one or more inflammatory and / or cancer cells in a subject in need thereof.
20. The composition according to any one of claims 1 to 18 for treating cancer.
21. 1. A composition for treating cancer, comprising a compound comprising a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, said dendrimer comprising a high density of surface hydroxyl groups, wherein an effective amount of said composition is administered to said subject; Optionally, the composition is administered to the subject systemically, or via an intraperitoneal, intravenous, intrathecal, intratumoral, or oral route; Optionally, the cancer is breast cancer, ovarian cancer, uterine cancer, prostate cancer, testicular germ cell tumors, brain cancer, gastric cancer, esophageal cancer, lung cancer, liver cancer, renal cell carcinoma, and colon cancer; and / or Optionally, the effective amount is effective to reduce tumor size. composition.
22. 1. A method of making a hydroxyl dendrimer covalently conjugated to one or more positron emission tomography (PET) imaging agents or one or more magnetic resonance imaging (MRI) contrast agents via an ether linkage, said method comprising etherification of one or more surface groups of said dendrimer prior to conjugation, optionally via one or more spacers, of said one or more surface groups to one or more PET imaging agents, said conjugation being via an ether linkage; Optionally, the PET imaging agent or the MRI contrast agent comprises a chelator selected from the group consisting of p-SCN-Bn-deferoxamine, diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), diaminedithiols, activated mercaptoacetyl-glycyl-glycyl-glycine (MAG3), and hydrazidonicotinamide (HYNIC); and / or Optionally, the PET imaging agent comprises a radionuclide selected from the group consisting of 64Cu, 89Zr, 90Y, 105Rh, 111In, 117mSn, 149Pm, 153Sm, 161Tb, 166Tb, 166Dy, 166Ho, 175Yb, 177Lu, 225Ac, 186 / 188Re, and 199Au; and / or Optionally, the MRI contrast agent comprises a metal selected from the group consisting of Gd, Mn, BaSO 4 , iron oxide, and iron platinum; and / or Optionally, the dendrimer is further complexed and / or conjugated to one or more therapeutic, prophylactic and / or diagnostic agents. method.
23. A composition for treating a neurodegenerative disorder, comprising a compound comprising a dendrimer conjugated to a radionuclide or an MRI contrast agent through an ester, ether, or amide linkage, said dendrimer comprising a high density of surface hydroxyl groups, and optionally the neurodegenerative disorder is Alzheimer's disease, or The neurodegenerative disorder is ALS. composition.
